-
In Memoriam: Brian G. Feagan, MD, FRCPC (1954-2025). Gastroenterology. 2026 Feb 12. Panaccione R, D'haens GR, Sands BE, Mcdonald JWD, Khanna R, Jairath V, Fletcher JG, Bruining D, Baker ME, Ma C, Rieder F, Sandborn WJ. PMID: 41686100.
-
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis. 2025 Oct 01; 31(10):2714-2724. Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, Danese S, Lee SJ, Kim SH, Bae YJ, Lee SH, Lee SG, Lee JH, Kim JM, Park GH, Lee J, Lee JH, Kim CY, Sands BE. PMID: 40300779; PMCID: PMC12558576.
-
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6). Colombel JF, Sandborn WJ, Schreiber S, Danese S, Klopocka M, Kierkus J, Kulynych R, Gonciarz M, Soltysiak A, Smolinski P, Sreckovic S, Valuyskikh E, Lahat A, Horynski M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB. PMID: 40243842; PMCID: PMC12134888.
-
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 Nov; 169(6):1282-1293. Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D'Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen BL, Colombel JF, D'Amico F, Dignass A, Dubinsky M, Fleshner P, Gearry RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, Magro F, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, van der Woude CJ, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C. PMID: 40446946; PMCID: PMC12354294.
-
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease. Inflamm Bowel Dis. 2025 Mar 03; 31(3):706-715. Khanna R, Feagan BG, Zou G, Stitt LW, McDonald JWD, Bressler B, Panaccione R, Shackelton LM, VanViegen T, Loftus EV, Daperno M, Jairath V, D'Haens G, Sandborn WJ. PMID: 38661492; PMCID: PMC11879229.
-
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 03; 10(3):210-221. Sands BE, Panaccione R, D'Haens G, Schreiber S, Jairath V, DuVall A, Kierkus J, Walczak M, Naik S, Gilder K, Lindstrom B, Ogilvie K, Sandborn WJ, Vermeire S, Rubin DT, Peyrin-Biroulet L, Danese S. PMID: 39793589.
-
Correction to: Genetic Risk, Dysbiosis, and Treatment Stratification Using Host Genome and Gut Microbiome in Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2024 12 01; 15(12):e00796. Moustafa A, Li W, Anderson EL, MWong EH, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter CJ, Nelson KE, Chang JT, Telenti A, Boland BS. PMID: 39656168; PMCID: PMC11671059.
-
Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy. Crohns Colitis 360. 2024 Oct; 6(4):otae052. Wong R, Charilaou P, Hemperly A, Qin L, Pan Y, Mathani P, Longman R, Boland BS, Dulai PS, Holmer AK, Lukin D, Singh S, Valasek MA, Sandborn WJ, Scherl E, Vande Casteele N, Battat R. PMID: 39679163; PMCID: PMC11645457.
-
A living organoid biobank of patients with Crohn's disease reveals molecular subtypes for personalized therapeutics. Cell Rep Med. 2024 Oct 15; 5(10):101748. Tindle C, Fonseca AG, Taheri S, Katkar GD, Lee J, Maity P, Sayed IM, Ibeawuchi SR, Vidales E, Pranadinata RF, Fuller M, Stec DL, Anandachar MS, Perry K, Le HN, Ear J, Boland BS, Sandborn WJ, Sahoo D, Das S, Ghosh P. PMID: 39332415; PMCID: PMC11513829.
-
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis. J Crohns Colitis. 2024 Sep 03; 18(9):1361-1370. Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Longman RS, Hyde CL, Hung KE. PMID: 38141256; PMCID: PMC11369066.
-
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis. J Crohns Colitis. 2024 Aug 06; 18(7):1091-1101. Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C, Miao Y, Ma T, Loftus EV, Sandborn WJ, Danese S, Abreu MT, Sands BE. PMID: 38310565; PMCID: PMC11302965.
-
Pangenome comparison of Bacteroides fragilis genomospecies unveils genetic diversity and ecological insights. mSystems. 2024 Jul 23; 9(7):e0051624. Oles RE, Carrillo Terrazas M, Loomis LR, Hsu C-Y, Tribelhorn C, Belda-Ferre P, Ea AC, Bryant M, Young JA, Carrow HC, Sandborn WJ, Dulai PS, Sivagnanam M, Pride D, Knight R, Chu H. PMID: 38934546; PMCID: PMC11265264.
-
Pathogenic Bacteroides fragilis strains can emerge from gut-resident commensals. bioRxiv. 2024 Jun 19. Oles RE, Terrazas MC, Loomis LR, Neal MJ, Paulchakrabarti M, Zuffa S, Hsu CY, Vasquez Ayala A, Lee MH, Tribelhorn C, Belda-Ferre P, Bryant M, Zemlin J, Young J, Dulai P, Sandborn WJ, Sivagnanam M, Raffatellu M, Pride D, Dorrestein PC, Zengler K, Choudhury B, Knight R, Chu H. PMID: 38948766; PMCID: PMC11213024.
-
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice. Nat Rev Gastroenterol Hepatol. 2024 Aug; 21(8):572-584. Bettenworth D, Baker ME, Fletcher JG, Jairath V, Lu C, Bemelman W, d'Haens G, d'Hoore A, Dignass A, Dotan I, Feakins R, Fleshner P, Ha C, Henderson G, Lyu R, Panes J, Rogler G, Mao R, Rimola J, Sandborn WJ, Ng SC, Siegmund B, Silverberg M, Taylor SA, Verstockt B, Gordon IO, Bruining DH, Feagan BG, Rieder F, Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium. PMID: 38831007; PMCID: PMC12063211.
-
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 03; 18(6):885-894. Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. PMID: 38245818; PMCID: PMC11147797.
-
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719. Vermeire S, Danese S, Sandborn WJ, Schreiber S, Hanauer S, D'Haens G, Nagy P, Thakur M, Bliss C, Cataldi F, Goetsch M, Gorelick KJ, Reinisch W. PMID: 38096402; PMCID: PMC11140626.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933. Hanauer SB, Sands BE, Schreiber S, Danese S, Klopocka M, Kierkus J, Kulynych R, Gonciarz M, Soltysiak A, Smolinski P, Sreckovic S, Valuyskikh E, Lahat A, Horynski M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Yang S, Lee J, Lee J, Kim JM, Park G, Sandborn WJ, Colombel JF. PMID: 38788861.
-
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis. Expert Rev Clin Pharmacol. 2024 Apr; 17(4):403-412. D'Haens G, Rosario M, Polhamus D, Dirks NL, Chen C, Kisfalvi K, Agboton C, Vermeire S, Feagan BG, Sandborn WJ. PMID: 38441048.
-
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. Eur J Gastroenterol Hepatol. 2024 Apr 01; 36(4):404-415. D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S. PMID: 38417060; PMCID: PMC10904001.
-
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterol. 2024 Feb 08; 11(1). Jairath V, Zou G, Wang Z, Adsul S, Colombel JF, D'Haens GR, Freire M, Moran GW, Peyrin-Biroulet L, Sandborn WJ, Sebastian S, Travis S, Vermeire S, Radulescu G, Sigler J, Hanžel J, Ma C, Sedano R, McFarlane SC, Arya N, Beaton M, Bossuyt P, Danese S, Green D, Harlan W, Horynski M, Klopocka M, Petroniene R, Silverberg MS, Wolanski L, Feagan BG. PMID: 38336367; PMCID: PMC10870790.
-
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv. 2023 Dec 21. Oles RE, Terrazas MC, Loomis LR, Hsu CY, Tribelhorn C, Ferre PB, Ea A, Bryant M, Young J, Carrow HC, Sandborn WJ, Dulai P, Sivagnanam M, Pride D, Knight R, Chu H. PMID: 38187556; PMCID: PMC10769428.
-
Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360. 2024 Jan; 6(1):otad076. Sandborn WJ, Sands BE, Uddin S, Qasim Khan RM, Sagar Mukherjee R. PMID: 38213631; PMCID: PMC10782208.
-
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 02; 9(2):133-146. Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI-1 Study Group. PMID: 38104569.
-
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. Am J Gastroenterol. 2024 05 01; 119(5):910-921. Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C. PMID: 38095692; PMCID: PMC11062601.
-
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. J Patient Rep Outcomes. 2023 11 14; 7(1):115. Feagan BG, Sandborn WJ, Sands BE, Liu Y, Vetter M, Mathias SD, Huang KG, Johanns J, Germinaro M, Han C. PMID: 37962770; PMCID: PMC10645698.
-
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 12; 165(6):1443-1457. Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A, QUASAR Study Group. PMID: 37659673.
-
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. Crohns Colitis 360. 2023 Jul; 5(3):otad034. Sandborn WJ, Chen J, Kisfalvi K, Loftus EV, D'Haens G, Candela N, Lasch K, Wolf DC, Uddin SM, Danese S. PMID: 37636008; PMCID: PMC10449415.
-
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. Clin Transl Gastroenterol. 2023 07 01; 14(7):e00578. Steere B, Schmitz J, Powell N, Higgs R, Gottlieb K, Liu Y, Jia B, Tuttle JL, Sandborn WJ, Sands BE, D'Haens G, Reinisch W, Krishnan V. PMID: 36881820; PMCID: PMC10371316.
-
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023 06 29; 388(26):2444-2455. D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE, LUCENT Study Group. PMID: 37379135.
-
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2. Colombel JF, Sands BE, Gasink C, Yeager B, Adedokun OJ, Izanec J, Ma T, Gao LL, Lee SD, Targan SR, Ghosh S, Hanauer SB, Sandborn WJ. PMID: 37391056.
-
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296. D'Haens G, Peyrin-Biroulet L, Marks DJB, Lisi E, Liefaard L, Beaton A, Srinivasan N, Bouma G, Prasad N, Cameron R, Kayali Z, Tarzi R, Hanauer S, Sandborn WJ. PMID: 37323059.
-
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. Clin Gastroenterol Hepatol. 2023 10; 21(11):2938-2950.e6. Khanna R, Ma C, Hogan M, Zou G, Bessissow T, Bressler B, Colombel JF, Danese S, Daperno M, East JE, Hookey L, Loftus EV, McDonald JWD, Panaccione R, Peyrin-Biroulet L, Rutter M, Sands BE, Vermeire S, Rémillard J, McFarlane SC, Sandborn WJ, D'Haens GR, Feagan BG, Jairath V. PMID: 37308036.
-
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. J Crohns Colitis. 2023 Apr 03; 17(3):338-351. Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. PMID: 36124702; PMCID: PMC10069618.
-
A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis. 2023 04 03; 29(4):555-562. Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. PMID: 35704691; PMCID: PMC10069658.
-
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. J Crohns Colitis. 2023 Mar 18; 17(2):211-220. Loftus EV, Vermeire S, Feagan BG, Le Brun FO, Oortwijn A, Moerch U, Sandborn WJ, Hibi T. PMID: 36006011; PMCID: PMC10024544.
-
A Living Organoid Biobank of Crohn's Disease Patients Reveals Molecular Subtypes for Personalized Therapeutics. bioRxiv. 2023 Mar 13. Tindle C, Katkar GD, Fonseca AG, Taheri S, Lee J, Maity P, Sayed IM, Ibeawuchi SR, Vidales E, Pranadinata RF, Fuller M, Stec DL, Anandachar MS, Perry K, Le HN, Ear J, Boland BS, Sandborn WJ, Sahoo D, Das S, Ghosh P. PMID: 36993763; PMCID: PMC10054961.
-
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 04 08; 401(10383):1159-1171. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. PMID: 36871574.
-
The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients. Pharmaceutics. 2023 Mar 02; 15(3). Park YS, Kang SB, Marchelletta RR, Penrose HM, Ruiter-Visser R, Jung B, Docherty MJ, Boland BS, Sandborn WJ, McCole DF. PMID: 36986672; PMCID: PMC10053841.
-
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023 04; 8(4):307-320. Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J, VEGA Study Group. PMID: 36738762.
-
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Sci Adv. 2023 01 20; 9(3):eadd1166. Mayer AT, Holman DR, Sood A, Tandon U, Bhate SS, Bodapati S, Barlow GL, Chang J, Black S, Crenshaw EC, Koron AN, Streett SE, Gambhir SS, Sandborn WJ, Boland BS, Hastie T, Tibshirani R, Chang JT, Nolan GP, Schürch CM, Rogalla S. PMID: 36662860; PMCID: PMC9858501.
-
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023 09; 21(10):2616-2628.e7. Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. PMID: 36623678.
-
High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients With Unexplained Moderate-Severe Abdominal Symptoms: A Prospective US Multisite Study. Gastroenterology. 2023 04; 164(4):680-683.e2. Talley NJ, Peterson KA, Genta RM, Chang AT, Dellon ES, Sandborn WJ, 019 Study Team, Lacy BE, Chehade M, Hirano I, Gonsalves N, Lembo A, Schmitt CM, Rothenberg ME, Jain N, Pletneva MA, Turner KO, Youngblood BA. PMID: 36574864.
-
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap Adv Gastroenterol. 2022; 15:17562848221136331. Sandborn WJ, Sands BE, Vermeire S, Leung Y, Guo X, Modesto I, Su C, Wang W, Panés J. PMID: 36506749; PMCID: PMC9726836.
-
Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023 08; 21(9):2359-2369.e5. Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, Zheng K, Syal G, Ha C, Fleshner P, McGovern D, Sauk JS, Limketkai B, Dulai PS, Boland BS, Eisenstein S, Ramamoorthy S, Melmed G, Mahadevan U, Sandborn WJ, Ohno-Machado L. PMID: 36343846; PMCID: PMC12145724.
-
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Jan; 8(1):43-55. Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group. PMID: 36240801.
-
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. Am J Gastroenterol. 2023 02 01; 118(2):317-328. Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, Narula N, Peerani F, Click BH, Coburn ES, Dang TT, Gold S, Agrawal M, Garg R, Aggarwal M, Mohammad D, Halloran B, Kochhar GS, Todorowski H, Ud Din NM, Izanec J, Teeple A, Gasink C, Muser E, Ding Z, Swaminath A, Lakhani K, Hogan D, Datta S, Ungaro RC, Boland BS, Bohm M, Fischer M, Sagi S, Afzali A, Ullman T, Lawlor G, Baumgart DC, Chang S, Hudesman D, Lukin D, Scherl EJ, Colombel JF, Sands BE, Siegel CA, Regueiro M, Sandborn WJ, Bruining D, Kane S, Loftus EV, Dulai PS. PMID: 36191274.
-
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022 10; 44(10):1336-1355. Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. PMID: 36150926.
-
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022 11; 7(11):1024-1035. Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganic I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. PMID: 36075249.
-
Reply. Gastroenterology. 2023 Jan; 164(1):166-168. D'Haens GR, Sandborn WJ. PMID: 36067821.
-
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331. Hanzel J, Jairath V, De Cruz P, Guizzetti L, Shackelton LM, Bossuyt P, Duijvestein M, Dulai PS, Grossmann J, Hirten RP, Khanna R, Panes J, Peyrin-Biroulet L, Regueiro M, Rubin DT, Singh S, Stidham RW, Sandborn WJ, Feagan BG, D'Haens GR, Ma C. PMID: 34791254; PMCID: PMC9756946.
-
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1338-1347. Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S. PMID: 34958359; PMCID: PMC9434448.
-
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. J Crohns Colitis. 2022 Aug 30; 16(8):1222-1234. Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Arasaradnam RP, Afif W, Peyrin-Biroulet L, Sands BE, Marano C. PMID: 35239968; PMCID: PMC9426670.
-
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. Am J Gastroenterol. 2023 01 01; 118(1):138-147. Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S. PMID: 36113491; PMCID: PMC9810009.
-
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568. Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M. PMID: 35963369.
-
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. J Crohns Colitis. 2022 Jul 14; 16(6):922-930. Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. PMID: 34850857.
-
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 09; 7(9):871-893. Kiran RP, Kochhar GS, Kariv R, Rex DK, Sugita A, Rubin DT, Navaneethan U, Hull TL, Ko HM, Liu X, Kachnic LA, Strong S, Iacucci M, Bemelman W, Fleshner P, Safyan RA, Kotze PG, D'Hoore A, Faiz O, Lo S, Ashburn JH, Spinelli A, Bernstein CN, Kane SV, Cross RK, Schairer J, McCormick JT, Farraye FA, Chang S, Scherl EJ, Schwartz DA, Bruining DH, Philpott J, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sandborn WJ, Silverberg MS, Pardi DS, Church JM, Shen B. PMID: 35798022.
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964. CORE-IBD Collaborators, Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. PMID: 35788348.
-
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis. 2022 07 01; 28(7):1034-1044. D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Schreiber S, Il Park D, Hébuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. PMID: 34427633; PMCID: PMC9247846.
-
Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. J Crohns Colitis. 2022 Jun 24; 16(5):717-736. Almradi A, Sedano R, Hogan M, Zou GY, MacDonald JK, Parker CE, Hanzel J, Crowley E, Singh S, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. PMID: 34758084.
-
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, SEAVUE Study Group. PMID: 35691323.
-
Simplified Machine Learning Models Can Accurately Identify High-Need High-Cost Patients With Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2022 07 01; 13(7):e00507. Nguyen NH, Patel S, Gabunilas J, Qian AS, Cecil A, Jairath V, Sandborn WJ, Ohno-Machado L, Chen PL, Singh S. PMID: 35905414; PMCID: PMC10476830.
-
Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Am J Gastroenterol. 2022 10 01; 117(10):1639-1647. Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk JS, Park S, Parekh N, Zheng K, Rudrapatna V, Syal G, Ha C, McGovern DP, Melmed GY, Fleshner P, Eisenstein S, Ramamoorthy S, Dulai PS, Boland BS, Grunvald E, Mahadevan U, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 35973139.
-
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. PMID: 35644154.
-
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. PMID: 35644155.
-
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023 01; 21(1):173-181.e5. Nguyen NH, Luo J, Paul P, Kim J, Syal G, Ha C, Rudrapatna V, Park S, Parekh N, Zheng K, Sauk JS, Limketkai B, Fleshner P, Eisenstein S, Ramamoorthy S, Melmed G, Dulai PS, Boland BS, Mahadevan U, Sandborn WJ, Ohno-Machado L, McGovern D, Singh S. PMID: 35644340; PMCID: PMC9701245.
-
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 06 04; 399(10341):2113-2128. Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. PMID: 35644166.
-
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis. 2022 May 10; 16(4):616-624. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. PMID: 34664635; PMCID: PMC9274823.
-
A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022 05 04; 28(5):788-800. Tse CS, Singh S, Sandborn WJ. PMID: 34244749.
-
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 07; 112(1):90-100. Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. PMID: 35380740; PMCID: PMC9322343.
-
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther. 2022 08; 56(3):463-476. Vande Casteele N, Sandborn WJ, Feagan BG, Vermeire S, Dulai PS, Yarur A, Roblin X, Ben-Horin S, Dotan I, Osterman MT, Rosario M, Osborn TM, Panes J, Lindner D, Agboton C. PMID: 35474325.
-
Disease Activity Indices for Pouchitis: A Systematic Review. Inflamm Bowel Dis. 2022 03 30; 28(4):622-638. Sedano R, Nguyen TM, Almradi A, Rieder F, Parker CE, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. PMID: 34180986; PMCID: PMC8972820.
-
Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2022 Mar 14; 16(3):398-413. Nguyen NH, Picetti D, Dulai PS, Jairath V, Sandborn WJ, Ohno-Machado L, Chen PL, Singh S. PMID: 34492100; PMCID: PMC8919806.
-
The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2022 Mar 14; 16(3):490-499. Ble A, Renzulli C, Cenci F, Grimaldi M, Barone M, Sedano R, Chang J, Nguyen TM, Hogan M, Zou G, MacDonald JK, Ma C, Sandborn WJ, Feagan BG, Merlo Pich E, Jairath V. PMID: 34508572; PMCID: PMC8919832.
-
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. J Crohns Colitis. 2022 Mar 14; 16(3):444-451. Sandborn WJ, Lewis JD, Panes J, Loftus EV, D'Haens G, Yu Z, Huang B, Lacerda AP, Pangan AL, Feagan BG. PMID: 34546360; PMCID: PMC8919823.
-
Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol. 2022 03 14; 5(1):231. Katkar GD, Sayed IM, Anandachar MS, Castillo V, Vidales E, Toobian D, Usmani F, Sawires JR, Leriche G, Yang J, Sandborn WJ, Das S, Sahoo D, Ghosh P. PMID: 35288651; PMCID: PMC8921270.
-
Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis. 2022 03 02; 28(3):364-372. Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, Sandborn WJ, Ma C. PMID: 33988697; PMCID: PMC8889287.
-
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply. Aliment Pharmacol Ther. 2022 03; 55(6):735-736. Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Meadows KT, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. PMID: 35245951.
-
Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. 2023 05; 21(5):1348-1350. Kayal M, Ungaro RC, Bader G, Colombel JF, Sandborn WJ, Stalgis C. PMID: 35245701.
-
Design of Clinical Trials for Mild to Moderate Crohn's Disease. Gastroenterology. 2022 06; 162(7):1800-1814.e1. Hanzel J, Ma C, Jairath V, IBD Trial Design Group. PMID: 35240140.
-
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology. 2022 06; 162(7):1891-1910. Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Sanchez Gonzalez Y, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. PMID: 35227777.
-
Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2022 Feb 23; 16(2):224-243. Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. PMID: 34309658.
-
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1. Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O'Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L. PMID: 35189386.
-
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8. Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG, GALAXI-1 Investigators. PMID: 35134323.
-
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890. D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. PMID: 35122766.
-
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022 02; 7(2):171-185. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L, International Consortium for Therapeutic Drug Monitoring. PMID: 35026171; PMCID: PMC10187071.
-
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022 Jan 28; 16(1):27-38. Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. PMID: 34402887; PMCID: PMC8797168.
-
Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022 02; 7(2):262-276. Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, Batachari LE, Malfavon M, Zhu Q, Weldon K, Humphrey G, Carrillo-Terrazas M, Goldasich LD, Bryant M, Raffatellu M, Quinn RA, Gewirtz AT, Chassaing B, Chu H, Sandborn WJ, Dorrestein PC, Knight R, Gonzalez DJ. PMID: 35087228; PMCID: PMC8852248.
-
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261. Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L. PMID: 35051383.
-
Ozanimod for Ulcerative Colitis. Reply. N Engl J Med. 2022 01 13; 386(2):194-195. Sandborn WJ, Danese S. PMID: 35020995.
-
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(4):401-411. Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. PMID: 35014040; PMCID: PMC9305136.
-
Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. Gastroenterology. 2022 04; 162(4):1005-1018. Sedano R, Jairath V, Ma C, IBD Trial Design Group. PMID: 34998800.
-
Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol. 2022 01 01; 117(1):78-97. Nguyen NH, Martinez I, Atreja A, Sitapati AM, Sandborn WJ, Ohno-Machado L, Singh S. PMID: 34751673; PMCID: PMC8987011.
-
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs. 2022 Jan; 36(1):85-93. Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. PMID: 34951696; PMCID: PMC9826742.
-
Class Ib MHC-Mediated Immune Interactions Play a Critical Role in Maintaining Mucosal Homeostasis in the Mammalian Large Intestine. Immunohorizons. 2021 12 15; 5(12):953-971. Dasgupta S, Maricic I, Tang J, Wandro S, Weldon K, Carpenter CS, Eckmann L, Rivera-Nieves J, Sandborn W, Knight R, Dorrestein P, Swafford AD, Kumar V. PMID: 34911745; PMCID: PMC10026853.
-
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021; 14:17562848211059954. Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. PMID: 34917173; PMCID: PMC8669878.
-
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022 02; 55(4):464-478. Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. PMID: 34854095; PMCID: PMC9300081.
-
No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. Dig Dis Sci. 2022 07; 67(7):3115-3123. Picetti D, Kim J, Zhu W, Sandborn WJ, Jairath V, Singh S. PMID: 34797442; PMCID: PMC9117569.
-
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs. 2021 Nov; 35(6):715-733. Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. PMID: 34797516; PMCID: PMC9826743.
-
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 02; 7(2):128-140. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group. PMID: 34798039.
-
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95. Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. PMID: 34774224.
-
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology. 2022 02; 162(2):495-508. Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. PMID: 34748774.
-
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 12; 6(12):1002-1014. Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. PMID: 34688373; PMCID: PMC8933137.
-
Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 10 18; 27(10):1626-1633. Singh S, Heien HC, Sangaralingham L, Shah ND, Lai JC, Sandborn WJ, Moore AA. PMID: 33325507; PMCID: PMC8522787.
-
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 12; 54(11-12):1442-1453. Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. PMID: 34614208; PMCID: PMC9291991.
-
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291. Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study Group. PMID: 34587385.
-
Correction to: Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 Sep; 66(9):3216. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 33555517.
-
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology. 2021 12; 161(6):1853-1864.e10. Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R, Kanwar B, Shames R, D'Haens G, Schreiber S, Danese S, Feagan B, Pai RK, Liu DY, Gupta S. PMID: 34474038.
-
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849. Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J, Farraye FA, Kiran RP, Fleshner P, Rosh J, Shah SA, Chang S, Scherl E, Pardi DS, Schwartz DA, Kotze PG, Bruining DH, Kane SV, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, McCormick JT, Picoraro JA, Silverberg MS, Bernstein CN, Sandborn WJ, Vermeire S. PMID: 34416186.
-
Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies. Dig Dis Sci. 2022 06; 67(6):2451-2461. Tsai L, Nguyen NH, Ma C, Prokop LJ, Sandborn WJ, Singh S. PMID: 34379220; PMCID: PMC8831664.
-
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol. 2021 08 01; 116(8):1709-1719. Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. PMID: 34587127; PMCID: PMC8481677.
-
Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. Inflamm Bowel Dis. 2021 07 27; 27(8):1277-1284. Yoon H, Jangi S, Dulai PS, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33236763; PMCID: PMC8314112.
-
Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. Inflamm Bowel Dis. 2021 07 27; 27(8):1215-1223. Rozich JJ, Luo J, Dulai PS, Collins AE, Pham L, Boland BS, Sandborn WJ, Singh S. PMID: 33252124; PMCID: PMC8314101.
-
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis. 2021 07 27; 27(8):1346-1355. Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. PMID: 33051647; PMCID: PMC8314098.
-
Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun. 2021 07 12; 12(1):4246. Sahoo D, Swanson L, Sayed IM, Katkar GD, Ibeawuchi SR, Mittal Y, Pranadinata RF, Tindle C, Fuller M, Stec DL, Chang JT, Sandborn WJ, Das S, Ghosh P. PMID: 34253728; PMCID: PMC8275683.
-
Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2021 07 06; 12(7):e00380. Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 34228004; PMCID: PMC8260899.
-
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129. Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. PMID: 33438008; PMCID: PMC8256627.
-
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141. Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. PMID: 33290538; PMCID: PMC8256630.
-
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis. 2021 Jun 22; 15(6):950-959. Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. PMID: 33475734; PMCID: PMC8218705.
-
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis. 2021 Jun 22; 15(6):938-949. Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Klopocka M, Tarabar D, Vanásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. PMID: 33599720; PMCID: PMC8218706.
-
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm Bowel Dis. 2021 06 15; 27(7):994-1007. Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. PMID: 32964215; PMCID: PMC8205635.
-
National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. Inflamm Bowel Dis. 2021 06 15; 27(7):1068-1078. Nguyen NH, Khera R, Dulai PS, Boland BS, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 33051681; PMCID: PMC8205631.
-
Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort. Inflamm Bowel Dis. 2021 06 15; 27(7):1026-1034. Nguyen NH, Luo J, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32944753; PMCID: PMC8205632.
-
Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022 06; 67(6):2039-2048. Nguyen NH, Zhang X, Long MD, Sandborn WJ, Kappelman MD, Singh S. PMID: 34110539; PMCID: PMC8986995.
-
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 06 19; 397(10292):2372-2384. Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. PMID: 34090625.
-
Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022 06; 67(6):2510-2516. Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 34085174; PMCID: PMC8933138.
-
International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. Gut. 2022 03; 71(3):479-486. Gordon IO, Bettenworth D, Bokemeyer A, Srivastava A, Rosty C, de Hertogh G, Robert ME, Valasek MA, Mao R, Li J, Harpaz N, Borralho P, Pai RK, Odze R, Feakins R, Parker CE, Guizzetti L, Nguyen T, Shackelton LM, Sandborn WJ, Jairath V, Baker M, Bruining D, Fletcher JG, Feagan BG, Pai RK, Rieder F, Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. PMID: 33952604; PMCID: PMC8903083.
-
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2021 06; 6(6):482-497. Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T, Bortlik M, Liu X, Levy AN, González Suárez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN. PMID: 33872568.
-
Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. Inflamm Bowel Dis. 2021 04 15; 27(5):639-646. Dulai PS, Jairath V, Zou G, Stitt LW, Khanna R, Sandborn WJ, Feagan BG, Singh S. PMID: 32592481; PMCID: PMC8243599.
-
Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity. Inflamm Bowel Dis. 2021 04 15; 27(5):603-616. Fang X, Vázquez-Baeza Y, Elijah E, Vargas F, Ackermann G, Humphrey G, Lau R, Weldon KC, Sanders JG, Panitchpakdi M, Carpenter C, Jarmusch AK, Neill J, Miralles A, Dulai P, Singh S, Tsai M, Swafford AD, Smarr L, Boyle DL, Palsson BO, Chang JT, Dorrestein PC, Sandborn WJ, Knight R, Boland BS. PMID: 33026068; PMCID: PMC8047854.
-
Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. J Crohns Colitis. 2021 Apr 06; 15(4):567-574. Jangi S, Holmer AK, Dulai PS, Boland BS, Collins AE, Pham L, Sandborn WJ, Singh S. PMID: 32914194; PMCID: PMC8023862.
-
Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol. 2022 07; 20(7):1436-1449. Battat R, Sandborn WJ. PMID: 33819666.
-
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. Aliment Pharmacol Ther. 2021 04; 53(8):957-958. Jangi S, Yoon H, Dulai P, Valasek M, Boland B, Jairath V, Feagan B, Sandborn W, Singh S. PMID: 33745174.
-
The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. Gastroenterol Hepatol (N Y). 2021 Apr; 17(4 Suppl 4):3-13. Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR. PMID: 34135718; PMCID: PMC8191814.
-
Drug development for ulcerative proctitis: current concepts. Gut. 2021 07; 70(7):1203-1209. Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. PMID: 33789968.
-
Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut. 2022 06; 71(6):1078-1087. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai PS. PMID: 33766910.
-
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Aliment Pharmacol Ther. 2021 05; 53(10):1108-1117. Sedano R, Ma C, Pai RK, D' Haens G, Guizzetti L, Shackelton LM, Remillard J, Gionchetti P, Gordon IO, Holubar S, Kayal M, Lauwers GY, Pai RK, Pardi DS, Samaan MA, Schaeffer DF, Shen B, Silverberg MS, Feagan BG, Sandborn WJ, Jairath V. PMID: 33735522.
-
Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology. 2021 07; 161(1):107-115.e3. Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S. PMID: 33744307; PMCID: PMC8238837.
-
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 03; 20(3):591-601.e8. Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. PMID: 33684552.
-
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2022 02; 20(2):e74-e88. Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 33640480; PMCID: PMC8384969.
-
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4. Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG, Lynch JP. PMID: 33618023; PMCID: PMC8374005.
-
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology. 2021 06; 160(7):2291-2302. Ma C, Sedano R, Almradi A, Vande Casteele N, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. PMID: 33610533; PMCID: PMC8851891.
-
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A, International Organization for the Study of IBD. PMID: 33359090.
-
Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 04; 20(4):e750-e760. Jangi S, Holmer AK, Dulai PS, Boland B, Valasek M, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33556578; PMCID: PMC9550577.
-
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 03; 10(3):229-240. Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. PMID: 33513294; PMCID: PMC7986169.
-
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Aliment Pharmacol Ther. 2021 04; 53(7):784-793. Almradi A, Ma C, D'Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. PMID: 33410551.
-
A double-blind, 377-subject randomized study identifies Ruminococcus, Coprococcus, Christensenella, and Collinsella as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides. Gut Microbes. 2021 Jan-Dec; 13(1):1957536. Azcarate-Peril MA, Roach J, Marsh A, Chey WD, Sandborn WJ, Ritter AJ, Savaiano DA, Klaenhammer TR. PMID: 34365905; PMCID: PMC8354614.
-
Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. Gastrointest Endosc. 2021 01; 93(1):183-186. Jairath V, Zou GY, Ma C, Feagan BG, Sandborn WJ. PMID: 33353616.
-
Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. Clin Gastroenterol Hepatol. 2022 01; 20(1):236-238. Hanzel J, Ma C, Zou G, Singh S, Dulai PS, Feagan BG, D'Haens GR, Sandborn WJ, Jairath V. PMID: 33346141.
-
Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021 02; 53(3):374-382. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. PMID: 33314269; PMCID: PMC8041067.
-
Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):447-454.e1. Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 33279779; PMCID: PMC8588993.
-
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ, Crohn’s Colitis Foundation Clinical Research Alliance. PMID: 33227283; PMCID: PMC7956164.
-
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Ther Adv Gastroenterol. 2020; 13:1756284820971214. Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 33240396; PMCID: PMC7675888.
-
Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. Clin Gastroenterol Hepatol. 2021 10; 19(10):2031-2045.e11. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, Feagan BG, Jairath V, Sandborn WJ, Singh S. PMID: 33127595; PMCID: PMC8934200.
-
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 08; 20(8):1821-1830.e3. Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. PMID: 33127596.
-
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020 12; 52(11-12):1658-1675. Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam RP, Sands BE, Marano C. PMID: 33086438; PMCID: PMC8776399.
-
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):126-135. Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 33039584; PMCID: PMC8026779.
-
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol. 2020 12; 5(12):1063-1075. Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W, CONDUCT study group. PMID: 33031757.
-
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther. 2020 11; 52(10):1574-1582. Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. PMID: 32981088; PMCID: PMC8007067.
-
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology. 2020 12; 159(6):2013-2018.e7. Abreu MT, Sandborn WJ, IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group. PMID: 32961246.
-
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):105-115.e14. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. PMID: 32950748.
-
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis. 2020 09 18; 26(10):1562-1571. Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. PMID: 32105310; PMCID: PMC7500520.
-
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281. Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. PMID: 32179906.
-
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16; 14(9):1202-1213. Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. PMID: 32161949; PMCID: PMC7493219.
-
Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365. Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. PMID: 32876349; PMCID: PMC7540482.
-
Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 08; 66(8):2564-2569. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 32875527; PMCID: PMC7927417.
-
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064. Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. PMID: 32853634.
-
Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020 08 21; 5(50). Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, Kim ES, Limary AE, Jin W, Milner JJ, Yu B, Patel SA, Louis TL, Tysl T, Kurd NS, Bortnick A, Quezada LK, Kanbar JN, Miralles A, Huylebroeck D, Valasek MA, Dulai PS, Singh S, Lu LF, Bui JD, Murre C, Sandborn WJ, Goldrath AW, Yeo GW, Chang JT. PMID: 32826341; PMCID: PMC7733868.
-
Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2020 08 20; 26(9):1429-1435. Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. PMID: 31748806; PMCID: PMC7441095.
-
Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 10; 19(10):2054-2063.e14. Qian AS, Nguyen NH, Elia J, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32801013; PMCID: PMC7930013.
-
Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. Br J Clin Pharmacol. 2021 03; 87(3):1141-1149. Vande Casteele N, Jakate A, McNamee B, Sandborn WJ. PMID: 32671846; PMCID: PMC9328660.
-
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Aliment Pharmacol Ther. 2020 09; 52(6):1008-1016. Jangi S, Yoon H, Dulai PS, Valasek M, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33119168; PMCID: PMC8965793.
-
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. Gastroenterology. 2021 01; 160(1):115-127.e30. Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. PMID: 32763240; PMCID: PMC7402096.
-
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Aliment Pharmacol Ther. 2020 08; 52(3):568-569. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32656846.
-
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther. 2020 08; 52(4):669-681. Bohm M, Xu R, Zhang Y, Varma S, Fischer M, Kochhar G, Boland B, Singh S, Hirten R, Ungaro R, Shmidt E, Lasch K, Jairaith V, Hudesman D, Chang S, Lukin D, Swaminath A, Sands BE, Colombel JF, Kane S, Loftus EV, Shen B, Siegel CA, Sandborn WJ, Dulai PS, VICTORY Collaboration. PMID: 32656800; PMCID: PMC7496810.
-
No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020 08; 52(3):481-491. Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. PMID: 32573825; PMCID: PMC8015755.
-
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. 2020 10; 159(4):1262-1275.e7. Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 32585306; PMCID: PMC7658293.
-
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020 09; 5(9):819-828. Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. PMID: 32553149.
-
Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 07; 19(7):1377-1386.e5. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32526341; PMCID: PMC7987215.
-
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. Aliment Pharmacol Ther. 2020 06; 51(11):1209-1210. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 32424928.
-
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol. 2020 06; 115(6):885-894. Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. PMID: 32384283; PMCID: PMC7274901.
-
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Adv Ther. 2020 07; 37(7):3417-3431. Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, Tatro AR, Etrolizumab Global Steering Committee. PMID: 32445184; PMCID: PMC7467434.
-
Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1170-1179.e10. Dulai PS, Sandborn WJ, Murphy J. PMID: 32437872.
-
Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2021 06; 19(6):1209-1217.e2. Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. PMID: 32376505.
-
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Aliment Pharmacol Ther. 2020 05; 51(10):997-998. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 32338784.
-
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. Am J Gastroenterol. 2020 05; 115(5):738-745. Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, D'Haens G. PMID: 31850931.
-
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 03; 19(3):511-518.e6. Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. PMID: 32348905; PMCID: PMC7606215.
-
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020 06; 51(11):1031-1038. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32329532; PMCID: PMC8032452.
-
Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2020 06; 51(11):1047-1066. Dulai PS, Jairath V, Khanna R, Ma C, McCarrier KP, Martin ML, Parker CE, Morris J, Feagan BG, Sandborn WJ. PMID: 32319120; PMCID: PMC7317756.
-
Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients. Nutrients. 2020 Apr 10; 12(4). Chey W, Sandborn W, Ritter AJ, Foyt H, Azcarate-Peril MA, Savaiano DA. PMID: 32290344; PMCID: PMC7231374.
-
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 07; 13(4):743-751. Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. PMID: 32100960; PMCID: PMC7359948.
-
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020 04; 72(4):561-576. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR. PMID: 30875456; PMCID: PMC6745288.
-
Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis. 2020 03 04; 26(4):515-523. George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. PMID: 31504528; PMCID: PMC8127062.
-
Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin Gastroenterol Hepatol. 2020 10; 18(11):2437-2447.e6. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. PMID: 32142940; PMCID: PMC7490750.
-
Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020 03; 579(7797):123-129. Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK, Downes M, Welch RD, Quinn M, Humphrey G, Panitchpakdi M, Weldon KC, Aksenov A, da Silva R, Avila-Pacheco J, Clish C, Bae S, Mallick H, Franzosa EA, Lloyd-Price J, Bussell R, Thron T, Nelson AT, Wang M, Leszczynski E, Vargas F, Gauglitz JM, Meehan MJ, Gentry E, Arthur TD, Komor AC, Poulsen O, Boland BS, Chang JT, Sandborn WJ, Lim M, Garg N, Lumeng JC, Xavier RJ, Kazmierczak BI, Jain R, Egan M, Rhee KE, Ferguson D, Raffatellu M, Vlamakis H, Haddad GG, Siegel D, Huttenhower C, Mazmanian SK, Evans RM, Nizet V, Knight R, Dorrestein PC. PMID: 32103176; PMCID: PMC7252668.
-
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020 06; 158(8):2139-2149.e14. Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR. PMID: 32092309.
-
Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J. 2020 09; 287(18):3967-3988. Sayed IM, Suarez K, Lim E, Singh S, Pereira M, Ibeawuchi SR, Katkar G, Dunkel Y, Mittal Y, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. PMID: 32003126; PMCID: PMC7390677.
-
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 12; 18(13):2952-2961.e8. Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. PMID: 32062041; PMCID: PMC7899124.
-
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020 06; 158(8):2123-2138.e8. Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. PMID: 32044319.
-
Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther. 2020 01; 42(1):157-174.e4. Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. PMID: 31982148.
-
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020 04; 5(4):393-405. Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ. PMID: 31954438.
-
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 09; 18(10):2179-2191.e6. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. PMID: 31945470; PMCID: PMC8022894.
-
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313. Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ. PMID: 31644790.
-
Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastroenterol. 2020 03; 18(1):15-32. Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. PMID: 31902071.
-
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. PMID: 31158271.
-
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2020 03; 51(5):553-564. Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F, GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. PMID: 31867766; PMCID: PMC7028036.
-
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 09; 18(10):2244-2255.e9. Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. PMID: 31816446.
-
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020 02; 51(4):435-445. Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. PMID: 31755121; PMCID: PMC6989392.
-
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):550-561. Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. PMID: 31711921.
-
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. 2020 02; 158(3):515-526.e10. D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. PMID: 31711925.
-
Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. Genome Biol. 2019 10 31; 20(1):226. Sanders JG, Nurk S, Salido RA, Minich J, Xu ZZ, Zhu Q, Martino C, Fedarko M, Arthur TD, Chen F, Boland BS, Humphrey GC, Brennan C, Sanders K, Gaffney J, Jepsen K, Khosroheidari M, Green C, Liyanage M, Dang JW, Phelan VV, Quinn RA, Bankevich A, Chang JT, Rana TM, Conrad DJ, Sandborn WJ, Smarr L, Dorrestein PC, Pevzner PA, Knight R. PMID: 31672156; PMCID: PMC6822431.
-
Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol Hepatol. 2020 05; 18(6):1268-1279. Nguyen NH, Singh S, Sandborn WJ. PMID: 31676360; PMCID: PMC7183879.
-
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020 01; 51(2):271-280. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 31660640; PMCID: PMC9328429.
-
US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 10 18; 25(11):1828-1837. Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. PMID: 31039246; PMCID: PMC6799945.
-
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis. 2019 10 18; 25(11):1854-1861. Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. PMID: 31050734; PMCID: PMC6799947.
-
Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. Inflamm Bowel Dis. 2019 10 18; 25(11):1773-1779. Schwartz DA, Tagarro I, Carmen Díez M, Sandborn WJ. PMID: 31216573; PMCID: PMC6799946.
-
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 11; 50(10):1068-1076. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 31599001; PMCID: PMC6899755.
-
Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020 01; 158(1):76-94.e2. Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. PMID: 31593701.
-
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, UNIFI Study Group. PMID: 31553833.
-
Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 07; 18(8):1760-1768.e1. Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. PMID: 31546056; PMCID: PMC7992966.
-
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233. Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. PMID: 30726897; PMCID: PMC6751337.
-
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):537-549.e10. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. PMID: 31493397.
-
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019 10; 50(8):848-857. Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. PMID: 31483522; PMCID: PMC7083298.
-
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. Clin Gastroenterol Hepatol. 2020 08; 18(9):2139-2141.e2. Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackelton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR. PMID: 31473359.
-
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):562-572.e12. Sandborn WJ, Baert F, Danese S, Krznaric Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. PMID: 31470005.
-
Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020 08; 18(9):1939-1948.e7. Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S. PMID: 31470176; PMCID: PMC7044053.
-
Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2020 May; 18(5):1121-1132.e2. Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V. PMID: 31442599.
-
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 08 20; 25(9):1532-1540. Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G. PMID: 30753466.
-
Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs. 2019 Aug; 79(12):1321-1335. Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. PMID: 31317509.
-
Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology. 2019 11; 157(5):1233-1244.e5. Hindryckx P, Jairath V, Zou G, Feagan BG, Sandborn WJ, Stoker J, Khanna R, Stitt L, van Viegen T, Shackelton LM, Taylor SA, Santillan C, Mearadji B, D'Haens G, Richard MP, Panes J, Rimola J. PMID: 31336124.
-
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology. 2019 10; 157(4):1019-1031.e7. Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. PMID: 31279870.
-
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. PMID: 31279871.
-
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1. Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. PMID: 31228441.
-
Correction: Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1011. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 31033518.
-
Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1010. Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 31033520.
-
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019; 5(1):e000942. Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP. PMID: 31245056; PMCID: PMC6560674.
-
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis. 2019 May 27; 13(6):725-734. Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. PMID: 30753371; PMCID: PMC6535500.
-
Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 02; 18(2):424-431.e7. Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. PMID: 31108227; PMCID: PMC6858937.
-
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019 05; 114(5):733-745. Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. PMID: 30694863.
-
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Aliment Pharmacol Ther. 2019 06; 49(11):1401-1409. Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G. PMID: 30983024.
-
Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019 04; 114(4):630-639. Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S. PMID: 30865012; PMCID: PMC6824268.
-
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci. 2019 09; 64(9):2478-2488. Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. PMID: 30923985; PMCID: PMC6704097.
-
Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019 05; 49(9):1188-1194. Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, Feagan BG, Jairath V. PMID: 30891808; PMCID: PMC6461484.
-
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol. 2019; 10:212. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30930775; PMCID: PMC6425155.
-
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020 01; 18(1):69-81.e3. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. PMID: 30876964; PMCID: PMC8011651.
-
Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019 Feb 01; 13(2):172-181. Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. PMID: 30285104; PMCID: PMC6357899.
-
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 10; 25(2):410-420. Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 30295781; PMCID: PMC6327228.
-
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 01 10; 25(2):270-282. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30165490; PMCID: PMC6327230.
-
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 11; 17(12):2497-2505.e1. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R. PMID: 30625408; PMCID: PMC7026826.
-
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflamm Bowel Dis. 2019 01 01; 25(1):163-171. Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. PMID: 29982631.
-
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57. Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. PMID: 30203005; PMCID: PMC6302953.
-
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Dec; 113(12):696. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 30390030; PMCID: PMC6455086.
-
Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2527-2542. Hemperly A, Sandborn WJ, Vande Casteele N. PMID: 29788338; PMCID: PMC11187819.
-
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019 03; 156(4):946-957.e18. Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. PMID: 30472236.
-
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 07; 17(8):1541-1550. Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. PMID: 30476584.
-
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2722-2730.e4. Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS. PMID: 30448597; PMCID: PMC6520204.
-
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018 Nov 09; 12(10):1158-1169. Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C, Peficitinib-UC Study Group. PMID: 29917064.
-
Metagenomics-Based, Strain-Level Analysis of Escherichia coli From a Time-Series of Microbiome Samples From a Crohn's Disease Patient. Front Microbiol. 2018; 9:2559. Fang X, Monk JM, Nurk S, Akseshina M, Zhu Q, Gemmell C, Gianetto-Hill C, Leung N, Szubin R, Sanders J, Beck PL, Li W, Sandborn WJ, Gray-Owen SD, Knight R, Allen-Vercoe E, Palsson BO, Smarr L. PMID: 30425690; PMCID: PMC6218438.
-
Definitions of response and remission for the Robarts Histopathology Index. Gut. 2019 11; 68(11):2101-2102. Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V. PMID: 30366909.
-
Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1814-1821.e1. Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. PMID: 30613004.
-
Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2019 02; 64(2):382-390. Ahmad W, Nguyen NH, Boland BS, Dulai PS, Pride DT, Bouland D, Sandborn WJ, Singh S. PMID: 30361807; PMCID: PMC6358459.
-
Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019 02; 89(2):215-237. Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ, Global Interventional Inflammatory Bowel Disease Group. PMID: 30365985.
-
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol. 2019 Jan; 4(1):63-70. Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG. PMID: 30343116.
-
Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2366-2376. Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J. PMID: 29889233; PMCID: PMC6185553.
-
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2461-2467. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. PMID: 29788240; PMCID: PMC6693035.
-
Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 03; 17(4):709-718.e7. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 30012429.
-
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 07; 17(8):1533-1540.e2. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 30268561; PMCID: PMC6594363.
-
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1. Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. PMID: 30267864.
-
Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019 01; 17(2):218-230. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. PMID: 30240894; PMCID: PMC6391518.
-
Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. Inflamm Bowel Dis. 2018 09 15; 24(10):2278-2284. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29788260; PMCID: PMC6140448.
-
Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. Proc Natl Acad Sci U S A. 2018 09 25; 115(39):E9192-E9200. Garcia-Carbonell R, Wong J, Kim JY, Close LA, Boland BS, Wong TL, Harris PA, Ho SB, Das S, Ernst PB, Sasik R, Sandborn WJ, Bertin J, Gough PJ, Chang JT, Kelliher M, Boone D, Guma M, Karin M. PMID: 30209212; PMCID: PMC6166836.
-
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42. Hanauer SB, Sandborn WJ, Lichtenstein GR. PMID: 30195449.
-
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018 10; 155(4):1045-1058. Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. PMID: 29909019.
-
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029. Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. PMID: 29767728; PMCID: PMC6113706.
-
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018 Aug 29; 12(9):1053-1066. Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C. PMID: 29917070.
-
Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 12; 16(12):1847-1850.e1. Singh S, Brill JV, Proudfoot JA, Metcalfe L, Vu L, Sandborn WJ, Kosinski LR. PMID: 30149146.
-
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 11; 3(11):742-753. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. PMID: 30122356; PMCID: PMC6821871.
-
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 08 16; 24(9):1876-1882. Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A. PMID: 29668916.
-
Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168. Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. PMID: 30076171.
-
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. J Crohns Colitis. 2018 Jul 30; 12(8):930-938. Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM. PMID: 29697818; PMCID: PMC6065484.
-
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. J Crohns Colitis. 2018 Jul 30; 12(8):883-895. Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG. PMID: 29726939.
-
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 10; 3(10):671-680. Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. PMID: 30056030.
-
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688. Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. PMID: 30022113.
-
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology. 2018 10; 155(4):1008-1011.e8. Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. PMID: 29981298.
-
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 09; 113(9):1345. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 29946178; PMCID: PMC6445254.
-
No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 Aug; 113(8):1197-1205. Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 29925913; PMCID: PMC7107271.
-
Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 08; 48(4):394-409. Singh S, Fumery M, Sandborn WJ, Murad MH. PMID: 29920733.
-
An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Aliment Pharmacol Ther. 2018 08; 48(3):347-357. Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V. PMID: 29920726; PMCID: PMC6043370.
-
Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018 06; 113(6):883-889. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29867171; PMCID: PMC7107273.
-
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 09; 155(3):687-695.e10. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. PMID: 29857091; PMCID: PMC6419724.
-
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 May 25; 12(6):635-643. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. PMID: 29370397; PMCID: PMC7189966.
-
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77. Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. PMID: 29797519; PMCID: PMC6032827.
-
Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. Inflamm Bowel Dis. 2018 05 18; 24(6):1316-1320. Fumery M, Patel NS, Boland BS, Dulai PS, Singh S, Sandborn WJ. PMID: 29697797; PMCID: PMC6231369.
-
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13(5):e0195123. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. PMID: 29771924; PMCID: PMC5957395.
-
A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. Gastroenterol Hepatol (N Y). 2018 May; 14(5 Suppl 2):1-12. Sandborn WJ, Abreu MT, Dubinsky MC. PMID: 29991933; PMCID: PMC6018319.
-
Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2018 04 27; 12(5):631. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 29566131.
-
Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(12):1578-1596. Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 29696670.
-
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. Inflamm Bowel Dis. 2018 04 23; 24(5):932-942. Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM. PMID: 29668919.
-
High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(11):1472-1479. Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, Singh S. PMID: 29665045; PMCID: PMC5992082.
-
Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointest Endosc. 2018 08; 88(2):360-369.e2. Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L, Bloom S, Pardi DS, Gionchetti P, Lindsay J, Travis S, Hart A, Silverberg MS, Feagan BG, D'Haens GR, Jairath V. PMID: 29660321.
-
Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. Am J Gastroenterol. 2018 04; 113(4):627-629. Park S, Evans E, Sandborn WJ, Boland B. PMID: 29610516.
-
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2018 03 28; 12(4):510. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 29385425.
-
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87. Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. PMID: 29601825.
-
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22. Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 29596987.
-
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 03 19; 24(4):871-876. Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochhar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV. PMID: 29509927.
-
Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018 03 19; 24(4):916-923. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29562273.
-
Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Mar; 16(1):129-146. Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. PMID: 29411220.
-
Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. Clin Gastroenterol Hepatol. 2018 08; 16(8):1284-1292.e30. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29474966; PMCID: PMC6056327.
-
Reliability of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018 Apr; 47(7):940-950. Warners MJ, Ambarus CA, Bredenoord AJ, Verheij J, Lauwers GY, Walsh JC, Katzka DA, Nelson S, van Viegen T, Furuta GT, Gupta SK, Stitt L, Zou G, Parker CE, Shackelton LM, D Haens GR, Sandborn WJ, Dellon ES, Feagan BG, Collins MH, Jairath V, Pai RK. PMID: 29460418.
-
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ. PMID: 29462395; PMCID: PMC6176880.
-
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. PMID: 29409871.
-
Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. J Crohns Colitis. 2018 Jan 24; 12(2):167-177. Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. PMID: 29028958; PMCID: PMC5881746.
-
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis. 2018 Jan 24; 12(2):188-196. D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. PMID: 28961770; PMCID: PMC5881743.
-
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783. Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. PMID: 29349829.
-
Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. Inflamm Bowel Dis. 2018 01 18; 24(2):440-449. Jairath V, Ordas I, Zou G, Panes J, Stoker J, Taylor SA, Santillan C, Horsthuis K, Samaan MA, Shackelton LM, Stitt LW, Hindryckx P, Khanna R, Sandborn WJ, D'Haens G, Feagan BG, Levesque BG, Rimola J. PMID: 29361096.
-
Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis. 2018 01 18; 24(2):277-285. Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. PMID: 29361090.
-
Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018 Jan 18; 9(1):e132. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland BS. PMID: 29345635; PMCID: PMC5795019.
-
Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Radiology. 2018 Mar; 286(3):776-799. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused Panel. PMID: 29319414.
-
Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology. 2018 Mar; 154(4):1172-1194. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused Panel. PMID: 29329905.
-
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis. 2018 Jan 05; 12(1):105-119. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. PMID: 28961959.
-
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):162-175. Singh S, Fumery M, Sandborn WJ, Murad MH. PMID: 29205406.
-
Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 12 04; 11(12):1510. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28453665; PMCID: PMC5951008.
-
Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 12; 56(12):1513-1523. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. PMID: 28353055.
-
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228. Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. PMID: 29159817.
-
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2018 01; 47(2):229-237. Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. PMID: 29159893; PMCID: PMC5765392.
-
Population Health Management for Inflammatory Bowel Disease. Gastroenterology. 2018 01; 154(1):37-45. Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. PMID: 29122544.
-
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. Clin Transl Gastroenterol. 2017 Nov 02; 8(11):e126. Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N. PMID: 29095427; PMCID: PMC5717516.
-
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 12 23; 390(10114):2779-2789. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. PMID: 29096949.
-
Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017 Nov; 112(11):1658-1669. Warners MJ, Hindryckx P, Levesque BG, Parker CE, Shackelton LM, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Bredenoord AJ, Jairath V. PMID: 29039850.
-
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018 10; 67(10):1824-1835. Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. PMID: 28982740; PMCID: PMC6145284.
-
Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. Gastrointest Endosc. 2017 12; 86(6):962-971. Kaltenbach T, Sandborn WJ. PMID: 28987547.
-
Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. Am J Gastroenterol. 2017 10; 112(10):1621. Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. PMID: 28978958; PMCID: PMC6389596.
-
Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017 09 08; 9:CD011572. Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28886205; PMCID: PMC6483671.
-
Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):603-626. Deepak P, Sandborn WJ. PMID: 28838418.
-
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 05; 16(5):637-647.e13. Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 28843356.
-
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 08 03; 377(5):496-7. Sandborn WJ, Su C, Panes J. PMID: 28767341.
-
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 28333288.
-
Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2017 Jul 21; 7:CD012351. Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. PMID: 28731502; PMCID: PMC6483549.
-
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28333362; PMCID: PMC5881669.
-
Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 07; 23(7):1047-1056. Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. PMID: 28410341.
-
Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis. 2017 Jul 01; 11(7):811-819. Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. PMID: 28333187.
-
The development of a magnetic resonance imaging index for fistulising Crohn's disease. Aliment Pharmacol Ther. 2017 09; 46(5):516-528. Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, Shackelton LM, Vandervoort MK, Khanna R, Santillan C, Rimola J, Hindryckx P, Nio CY, Sandborn WJ, D'Haens G, Feagan BG, Jairath V, Stoker J. PMID: 28653753.
-
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018 03; 16(3):343-356.e3. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. PMID: 28625817; PMCID: PMC6658168.
-
Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open. 2017 06 09; 7(6):e016146. Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG, Sandborn WJ, Feagan BG, Jairath V. PMID: 28601837; PMCID: PMC5726090.
-
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 08; 46(3):292-302. D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. PMID: 28568974.
-
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. PMID: 28527704.
-
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. PMID: 28467869.
-
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 06; 112(6):975. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28417993.
-
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017 04 29; 389(10080):1699-1709. Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. PMID: 28411872.
-
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis. 2017 Apr 01; 11(4):425-434. Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. PMID: 27815351; PMCID: PMC5881717.
-
Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424. Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683798.
-
Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683800.
-
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 04; 45(8):1058-1072. Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L. PMID: 28247573.
-
Head-to-head Comparative Studies: Challenges and Opportunities? J Crohns Colitis. 2017 Mar 01; 11(suppl_2):S567-S575. Peyrin-Biroulet L, Lopez A, Sandborn W. PMID: 27660343.
-
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 06; 66(6):1049-1059. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. PMID: 28209624; PMCID: PMC5532457.
-
Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Aliment Pharmacol Ther. 2017 04; 45(8):1021-1042. Jairath V, Zou G, Parker CE, MacDonald JK, Mosli MH, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Kherad O, Koutsoumpas A, Minas E, Restellini S, Samaan MA, Khanna R, Levesque BG, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28164348.
-
Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 03; 45(5):617-630. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. PMID: 28074618; PMCID: PMC6658182.
-
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Oct; 112(10):1584-1592. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28071654.
-
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2017 01; 23(1):97-106. Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. PMID: 27930408.
-
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2017 Jun; 15(6):850-856. Cotter TG, Gathaiya N, Catania J, Loftus EV, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS. PMID: 28013116; PMCID: PMC5440197.
-
Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2018 03; 67(3):441-446. Cotter TG, Binder M, Loftus EV, Abboud R, McNally MA, Smyrk TC, Tremaine WJ, Sandborn WJ, Pardi DS. PMID: 27965284.
-
Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017 02; 45(3):381-390. Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27928830; PMCID: PMC5253136.
-
Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 May; 15(5):665-674.e5. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27916678; PMCID: PMC5401779.
-
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):110-121. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. PMID: 27899815; PMCID: PMC5550405.
-
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, UNITI–IM-UNITI Study Group. PMID: 27959607.
-
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2017 01; 45(1):50-62. Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. PMID: 27883215; PMCID: PMC5157781.
-
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723. Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. PMID: 27585411.
-
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2018 01; 67(1):61-69. Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang CM, Parker C, Khanna R, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Lebwohl B, Leffler DA, Jairath V. PMID: 27799282.
-
Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. PMID: 27833391; PMCID: PMC5083805.
-
Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. PMID: 27780886.
-
Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 02; 152(2):374-388.e4. Abraham C, Dulai PS, Vermeire S, Sandborn WJ. PMID: 27780712; PMCID: PMC5287922.
-
Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. Dulai PS, Sandborn WJ, Gupta S. PMID: 27679553; PMCID: PMC5289746.
-
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 12; 111(12):1806-1815. Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. PMID: 27670599.
-
Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. Dulai PS, Sandborn WJ. PMID: 27461274; PMCID: PMC5901649.
-
Ozanimod Treatment for Ulcerative Colitis. N Engl J Med. 2016 08 25; 375(8):e17. Sandborn WJ, Feagan BG. PMID: 27557326.
-
Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 12; 32(12):1937-1941. Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ. PMID: 27494777.
-
Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016 Aug 08; (8):CD010642. Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. PMID: 27501379; PMCID: PMC7079710.
-
Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2017 02; 11(2):246-255. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 27487793.
-
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6. Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. PMID: 27416045; PMCID: PMC4949012.
-
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. PMID: 27400222; PMCID: PMC4949014.
-
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 09; 14(9):e121-2. Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. PMID: 27464592.
-
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017 Jan; 11(1):35-46. Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ. PMID: 27440869; PMCID: PMC5175493.
-
Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. J Crohns Colitis. 2016 Sep; 10(9):1006-14. Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim YI, Grover SC, McDonald JW, Shackelton LM, Khanna R, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 27385400.
-
The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 07; 22(7):1737-43. Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. PMID: 27306074.
-
The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7):438-41. Sandborn WJ. PMID: 27489526; PMCID: PMC4969780.
-
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 08; 111(8):1147-55. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. PMID: 27296941.
-
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 07; 44(2):157-69. Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. PMID: 27218676; PMCID: PMC5089609.
-
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 09; 14(9):1302-9. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. PMID: 27189916.
-
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A, TOUCHSTONE Study Group. PMID: 27144850.
-
Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 10; 14(10):1439-44. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 27155552; PMCID: PMC5028241.
-
Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 05; 111(5):746-8. Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn WJ, Harismendy O, Gupta S. PMID: 27151126; PMCID: PMC5824983.
-
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016 Apr 28; 7:e168. Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. PMID: 27124701; PMCID: PMC4855165.
-
How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. PMID: 26835982; PMCID: PMC5953904.
-
Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 07; 32(7):1233-41. Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. PMID: 26986449.
-
Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 05; 150(5):1056-1060. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. PMID: 27018491.
-
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, PREVENT Study Group. PMID: 26946343.
-
Reply. Gastroenterology. 2016 Apr; 150(4):1039. Jharap B, Colombel JF, Sandborn WJ. PMID: 26926449.
-
The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 05; 66(5):839-851. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. PMID: 26893500; PMCID: PMC5531223.
-
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. PMID: 26850690.
-
Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016 Mar; 15(3):173-83. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. PMID: 26822833; PMCID: PMC4890615.
-
Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG. PMID: 26746169; PMCID: PMC4957452.
-
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016 Apr; 10(4):418-28. Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. PMID: 26721935; PMCID: PMC4946756.
-
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. PMID: 26646934.
-
New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflamm Bowel Dis. 2015 Dec; 21(12):2948-57. Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. PMID: 26540276.
-
The Role of Psychosocial Care in Adapting to Health Care Reform. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2219-24. Reiss M, Sandborn WJ. PMID: 26589873.
-
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015 Nov 23; (11):CD001176. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. PMID: 26593456; PMCID: PMC4917283.
-
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. Aliment Pharmacol Ther. 2016 Jan; 43(1):61-72. Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn WJ, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J. PMID: 26548868.
-
Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. Boland BS, Dulai PS, Chang M, Sandborn WJ, Levesque BG. PMID: 26618431; PMCID: PMC5824985.
-
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):477-87.e9. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. PMID: 26522261.
-
Development and validation of a histological index for UC. Gut. 2017 01; 66(1):50-58. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. PMID: 26475633.
-
Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis. 2015 Oct; 21(10):2475-82. Gottlieb K, Travis S, Feagan B, Hussain F, Sandborn WJ, Rutgeerts P. PMID: 26086596.
-
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther. 2015 Nov; 42(10):1170-81. Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. PMID: 26400458.
-
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015 Nov; 42(10):1200-10. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 26388424.
-
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17. Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. PMID: 26386854; PMCID: PMC4621699.
-
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016 Jan; 150(1):96-102. Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. PMID: 26376350.
-
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016 09; 65(9):1447-55. Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. PMID: 26353983.
-
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 07; 386(10006):1825-34. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. PMID: 26342731.
-
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015 Nov; 42(9):1082-92. Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. PMID: 26381802; PMCID: PMC5049645.
-
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. PMID: 26303131.
-
Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Aliment Pharmacol Ther. 2015 Oct; 42(7):783-92. Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV. PMID: 26264359; PMCID: PMC6698449.
-
Reply: To PMID 24036054. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2382. Sandborn WJ, Bouguen G. PMID: 26247165.
-
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan; 83(1):188-97.e1-3. Rutgeerts P, Reinisch W, Colombel JF, Sandborn WJ, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. PMID: 26234693.
-
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015 Sep; 42(5):504-14. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn WJ, PURSUIT-IV study group. PMID: 26119226; PMCID: PMC4755132.
-
Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep; 9(9):738-46. Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. PMID: 26094251; PMCID: PMC4736820.
-
IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. Vande Casteele N, Sandborn WJ. PMID: 26077557.
-
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. PMID: 26071941.
-
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug; 42(3):330-42. Sandborn WJ, Melmed GY, McGovern DP, Loftus EV, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. PMID: 26031921.
-
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. PMID: 25989338; PMCID: PMC4450894.
-
Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. Vaughn BP, Sandborn WJ, Cheifetz AS. PMID: 25590953; PMCID: PMC4437804.
-
Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. PMID: 26005012; PMCID: PMC6709676.
-
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul; 42(2):188-202. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. PMID: 25996351; PMCID: PMC5032981.
-
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6):802-19; quiz 820. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. PMID: 25964225.
-
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ. PMID: 25956538; PMCID: PMC4584567.
-
Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016 07; 65(7):1119-25. Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. PMID: 25935574.
-
New Targets for Small Molecules in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 May; 11(5):338-40. Sandborn WJ. PMID: 27482177; PMCID: PMC4962684.
-
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. J Crohns Colitis. 2015 Aug; 9(8):601-6. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF. PMID: 25908718.
-
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015 Aug; 55(8):866-74. Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, Oliver R. PMID: 25735646; PMCID: PMC6680228.
-
Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Rev Clin Immunol. 2015 May; 11(5):637-57. Reinhard A, Sandborn WJ, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L. PMID: 25837708.
-
Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 25884529; PMCID: PMC6709861.
-
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 26491415; PMCID: PMC4609145.
-
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015 Apr; 41(8):734-46. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ. PMID: 25728587.
-
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015 Mar; 21(3):606-14. Bouguen G, Sninsky C, Tang KL, Colombel JF, D'Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn WJ. PMID: 25581826.
-
A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 05; 519(7541):57-62. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. PMID: 25731159; PMCID: PMC4447318.
-
Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis. 2015 Apr; 9(4):356-66. Bryant RV, Sandborn WJ, Travis SP. PMID: 25687206.
-
Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT. PMID: 25667416; PMCID: PMC4355235.
-
Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. PMID: 25545378; PMCID: PMC4404151.
-
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015 Apr; 148(4):740-750.e2. Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. PMID: 25644096.
-
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015 May; 47(5):356-64. Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. PMID: 25661014.
-
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar; 41(5):409-18. Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. PMID: 25588902; PMCID: PMC6681012.
-
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. PMID: 25222660.
-
Tailoring treatment to the individual patient: drug monitoring. Dig Dis. 2014; 32 Suppl 1:88-91. Sandborn WJ. PMID: 25531358.
-
Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014 Nov; 20(11):2092-103. Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. PMID: 25137418.
-
Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Inflamm Bowel Dis. 2014 Nov; 20(11):2132-41. Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. PMID: 25299543.
-
Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. PMID: 25192499; PMCID: PMC5557346.
-
Reproducibility of histological assessments of disease activity in UC. Gut. 2015 Nov; 64(11):1765-73. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG. PMID: 25360036.
-
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther. 2015 Jan; 41(1):77-86. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. PMID: 25348809.
-
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. PMID: 25336114; PMCID: PMC4602247.
-
A phase II study of laquinimod in Crohn's disease. Gut. 2015 Aug; 64(8):1227-35. D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG, Laquinimod for Crohn's Disease Investigators. PMID: 25281416; PMCID: PMC4515993.
-
A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014 Oct; 20(10):1850-61. Khanna R, Bouguen G, Feagan BG, D'Haens G, Sandborn WJ, Dubcenco E, Baker KA, Levesque BG. PMID: 25029615.
-
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015 Jan; 148(1):52-63.e3. Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J. PMID: 25241327.
-
Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):539-547.e2. Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F. PMID: 25245629.
-
An overview of magnetic resonance enterography for Crohn's disease. Dig Dis Sci. 2014 Sep; 59(9):2040-9. Pola S, Santillan C, Levesque BG, Feagan BG, Sandborn WJ. PMID: 24659238.
-
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014 Dec; 147(6):1296-1307.e5. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W. PMID: 25173754.
-
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov; 109(11):1771-80. Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. PMID: 25155227; PMCID: PMC4223868.
-
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct; 40(8):903-16. Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. PMID: 25146586.
-
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015 Jan; 148(1):37-51.e1. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. PMID: 25127678.
-
A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):731-8.e1-6; quiz e41. Yadav S, Dave M, Edakkanambeth Varayil J, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sweetser SR, Melton LJ, Sandborn WJ, Loftus EV. PMID: 25130936; PMCID: PMC4326614.
-
Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Aug; 10(8):478-489. Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 28845139; PMCID: PMC5566190.
-
A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014 Aug; 20(8):1465-71. Samaan MA, Mosli MH, Sandborn WJ, Feagan BG, D'Haens GR, Dubcenco E, Baker KA, Levesque BG. PMID: 24831558.
-
Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014 Sep; 147(3):702-5. Sandborn WJ. PMID: 25046160.
-
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):486-97. Wolf D, D'Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. PMID: 25041859.
-
Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):477-85. Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Chang JT. PMID: 25041724; PMCID: PMC4143528.
-
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn WJ, Sands BE. PMID: 24989100.
-
Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec; 63(12):1843-53. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. PMID: 24970900.
-
Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):603-17. Boland BS, Sandborn WJ, Chang JT. PMID: 25110261; PMCID: PMC4129380.
-
Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. Vande Casteele N, Sandborn WJ. PMID: 24951843.
-
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. PMID: 24859203.
-
Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014 Jul; 109(7):994-1004. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. PMID: 24842338.
-
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26; 384(9940):309-18. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. PMID: 24814090.
-
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35. Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. PMID: 24713173.
-
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1126-35. Levesque BG, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG. PMID: 24689499.
-
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. PMID: 24595615.
-
Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014 Mar; 20(3):564-75. Mosli MH, Feagan BG, Sandborn WJ, D'haens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. PMID: 24412993.
-
Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease. Dig Dis Sci. 2014 Jul; 59(7):1642-4. Pola S, Boland BS, Lin GY, Kuo A, Sandborn WJ. PMID: 24535249; PMCID: PMC5824981.
-
Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1246-56.e6. Williet N, Sandborn WJ, Peyrin-Biroulet L. PMID: 24534550.
-
Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014 Feb; 20(2):231-9. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. PMID: 24351660.
-
Taking a closer look at IBD. Gut. 2014 Feb; 63(2):e1. Egan LJ, Sandborn W. PMID: 24381262.
-
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1485-93.e2. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, Study A3921043 Investigators. PMID: 24480677.
-
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. PMID: 24394749.
-
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014 Apr; 146(4):941-9. Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. PMID: 24361468.
-
Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease. Dig Dis Sci. 2014 Apr; 59(4):838-49. Patel NS, Pola S, Muralimohan R, Zou GY, Santillan C, Patel D, Levesque BG, Sandborn WJ. PMID: 24323180.
-
IBD: Measuring what counts--endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol. 2014 Jan; 11(1):9-10. Khanna R, Levesque BG, Sandborn WJ. PMID: 24296581.
-
Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Jun; 12(6):978-85. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. PMID: 24246770.
-
Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):423-31.e1. Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X. PMID: 24184736.
-
Azathioprine-induced neuro-psychiatric disorders. J Crohns Colitis. 2014 Feb; 8(2):180. Bouguen G, Evans E, Sandborn WJ. PMID: 24103346.
-
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov; 38(10):1236-47. Panaccione R, Colombel JF, Sandborn WJ, D'Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. PMID: 24134498; PMCID: PMC4670480.
-
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):110-118.e3. Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. PMID: 24067881.
-
Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. PMID: 24036054.
-
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014 Jan; 63(1):88-95. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. PMID: 23974954.
-
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group. PMID: 23964933.
-
Is there still a role for thiopurines in Crohn's disease? Gastroenterology. 2013 Oct; 145(4):714-6. Rogler G, Sandborn WJ. PMID: 23973853.
-
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, GEMINI 1 Study Group. PMID: 23964932.
-
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5. Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases. PMID: 23954314.
-
Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013 Aug; 19(9):1858-66. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, Tremaine WJ, Sandborn WJ, Loftus EV. PMID: 23660997; PMCID: PMC4526131.
-
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. PMID: 23891974.
-
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Sep; 38(5):447-59. Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. PMID: 23848220.
-
Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):414-22.e5. Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. PMID: 23856361.
-
52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul; 19(8):1700-9. Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. PMID: 23665965.
-
Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis. 2013 Jul; 19(8):1645-53. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. PMID: 23598817.
-
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):96-109.e1. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P, PURSUIT-Maintenance Study Group. PMID: 23770005.
-
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. PMID: 23730956.
-
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):85-95; quiz e14-5. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P, PURSUIT-SC Study Group. PMID: 23735746.
-
Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun; 19(7):1384-9. Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. PMID: 23535248.
-
Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013 May; 108(5):857-8. Pola S, Fahmy M, Evans E, Tipps A, Sandborn WJ. PMID: 23644970.
-
Crohn's disease complicated by strictures: a systematic review. Gut. 2013 Jul; 62(7):1072-84. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. PMID: 23626373; PMCID: PMC4884453.
-
Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr; 19(5):1004-9. Sinakos E, Samuel S, Enders F, Loftus EV, Sandborn WJ, Lindor KD. PMID: 23502353.
-
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. PMID: 23511031; PMCID: PMC4596532.
-
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):149-157.e2. Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. PMID: 23528626.
-
Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis. 2013 Dec; 7(12):958-67. Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. PMID: 23517933.
-
Biosimilars in IBD: hope or expectation? Gut. 2013 Jun; 62(6):803-7. Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Löwenberg M, Jairath V, Travis SP, Sandborn WJ, Feagan BG, D'Haens GR. PMID: 23503043.
-
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin. 2013 May; 29(5):483-93. Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB. PMID: 23438483.
-
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar; 63(3):442-50. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. PMID: 23461895; PMCID: PMC3933070.
-
Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis. 2013 Mar; 19(3):550-3. Abboud R, Pardi DS, Tremaine WJ, Kammer PP, Sandborn WJ, Loftus EV. PMID: 23380937.
-
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):677-82. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV, Kappelman MD, Lewis JD, Parkos CA, Sartor RB, Challenges Workgroup. PMID: 23448796; PMCID: PMC3740342.
-
Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):E57-8. Fahmy M, Shabaik A, Sandborn WJ. PMID: 22552963.
-
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar; 63(3):433-41. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. PMID: 23436336; PMCID: PMC3933176.
-
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun; 11(6):654-66. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. PMID: 23357488.
-
Reply: budesonide. Gastroenterology. 2013 Mar; 144(3):e23-4. Sandborn WJ, Travis S, Ballard D. PMID: 23357061.
-
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54. Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM, Sandborn WJ, Loftus EV, Wolff BG, Smyrk TC, Itzkowitz SH, Rubin DT, Zou H, Mahoney DW, Ahlquist DA. PMID: 23347191; PMCID: PMC3869396.
-
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013 Apr; 93(4):324-5. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE, Clinical Pharmacogenetics Implementation Consortium. PMID: 23422873; PMCID: PMC3604643.
-
Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013 Feb; 108(2):256-9. Gentile NM, Abdalla AA, Khanna S, Smyrk TC, Tremaine WJ, Faubion WA, Kammer PP, Sandborn WJ, Loftus EV, Pardi DS. PMID: 23295275; PMCID: PMC3575108.
-
Deep remission: a new concept? Dig Dis. 2012; 30 Suppl 3:107-11. Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. PMID: 23295700.
-
The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis. 2012; 30 Suppl 3:140-4. Sandborn WJ. PMID: 23295705.
-
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012 Dec; 107(12):1770-6. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. PMID: 23211844.
-
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan; 37(2):204-13. Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. PMID: 23173821.
-
Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 24847181; PMCID: PMC4027896.
-
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, CERTIFI Study Group. PMID: 23075178.
-
Infliximab versus ciclosporin in severe ulcerative colitis. Lancet. 2012 Dec 01; 380(9857):1887-8. Levesque BG, Sandborn WJ. PMID: 23063315.
-
Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013 Jan; 108(1):90-8. Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. PMID: 23044768; PMCID: PMC3538174.
-
Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013 Mar; 58(3):797-806. Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. PMID: 23053885.
-
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012 Dec; 143(6):1461-9. D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M, International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee . PMID: 23000597.
-
Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012 Nov; 107(11):1693-701. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 22945286; PMCID: PMC3572861.
-
Crohn's disease. Lancet. 2012 Nov 03; 380(9853):1590-605. Baumgart DC, Sandborn WJ. PMID: 22914295.
-
Ulcerative colitis. Lancet. 2012 Nov 03; 380(9853):1606-19. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. PMID: 22914296.
-
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):49-54.e1. Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 22902762; PMCID: PMC10602401.
-
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16; 367(7):616-24. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W, Study A3921063 Investigators. PMID: 22894574.
-
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. PMID: 22890223; PMCID: PMC3438468.
-
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov; 143(5):1218-1226.e2. Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. PMID: 22892337.
-
Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1315-1325.e4. Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera-Nieves J, Chang JT, Evans E, Docherty M, Talamini M, Sandborn WJ. PMID: 22835577; PMCID: PMC4226798.
-
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Oct; 10(10):1079-87; quiz e85-6. Ordás I, Feagan BG, Sandborn WJ. PMID: 22813440.
-
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012 Sep; 36(6):569-74. Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH. PMID: 22779779.
-
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013 Apr; 7(3):213-21. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. PMID: 22704916.
-
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Jul; 107(7):1051-63. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. PMID: 22613901; PMCID: PMC3390465.
-
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012 Jul; 107(7):1064-77. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. PMID: 22565161.
-
Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012 May; 107(5):794-5. Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. PMID: 22552250.
-
Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012 Aug; 143(2):356-64.e1. Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS. PMID: 22549092.
-
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. PMID: 22504093.
-
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1253-9. Samuel S, Bruining DH, Loftus EV, Becker B, Fletcher JG, Mandrekar JN, Zinsmeister AR, Sandborn WJ. PMID: 22503995.
-
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012 Dec; 18(12):2203-8. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. PMID: 22419661.
-
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr; 91(4):635-46. Ordás I, Mould DR, Feagan BG, Sandborn WJ. PMID: 22357456.
-
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May; 142(5):1102-1111.e2. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. PMID: 22326435.
-
Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):117-9. Sandborn WJ. PMID: 22485079; PMCID: PMC3317509.
-
Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012 Feb; 6 Suppl 2:S224-34. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. PMID: 22463929.
-
IBD in 2011: Advances in IBD management--towards a tailored approach. Nat Rev Gastroenterol Hepatol. 2012 Jan 10; 9(2):70-2. Pineton de Chambrun GP, Sandborn WJ. PMID: 22230905.
-
Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):400-4. Nguyen DL, Sandborn WJ, Loftus EV, Larson DW, Fletcher JG, Becker B, Mandrekar J, Harmsen WS, Bruining DH. PMID: 22155562.
-
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. PMID: 22083024.
-
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb; 142(2):257-65.e1-3. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. PMID: 22062358.
-
Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012 Feb; 18(2):349-58. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. PMID: 22021134.
-
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. PMID: 21997563; PMCID: PMC3292713.
-
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011 Dec; 60(12):1754-63. Ordás I, Feagan BG, Sandborn WJ. PMID: 21997558.
-
Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2012 Jul; 18(7):1240-8. Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. PMID: 21928375.
-
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. PMID: 21894226.
-
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. PMID: 21848857.
-
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011 Sep; 106(9):1594-602; quiz 1593, 1603. Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. PMID: 21844919.
-
Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. Inflamm Bowel Dis. 2012 Apr; 18(4):795-6. Levesque BG, Sandborn WJ. PMID: 21739537.
-
Henoch-schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum. Dig Dis Sci. 2011 Jul; 56(7):2205-6. Samuel S, Loftus EV, Sandborn WJ. PMID: 21249449.
-
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. PMID: 21723220.
-
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17. Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, Zhou Q, Robinson AM. PMID: 21645018.
-
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012 Feb; 61(2):241-7. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. PMID: 21646246; PMCID: PMC3245899.
-
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):670-678.e3. Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. PMID: 21642014.
-
Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):679-683.e1. Bruining DH, Loftus EV, Ehman EC, Siddiki HA, Nguyen DL, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Sandborn WJ, Fletcher JG. PMID: 21621641.
-
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. PMID: 21484965.
-
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, American College of Gastroenterology IBD Task Force. PMID: 21472012.
-
Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012 Feb; 18(2):275-83. Garrity-Park M, Loftus EV, Sandborn WJ, Smyrk TC. PMID: 21425209.
-
Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012 Feb; 18(2):226-35. Kisiel JB, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 21416564.
-
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. PMID: 21407183.
-
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011 Apr; 106(4):674-84. Billioud V, Sandborn WJ, Peyrin-Biroulet L. PMID: 21407178.
-
Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel. Inflamm Bowel Dis. 2011 Mar; 17(3):778-86. Siddiki H, Fletcher JG, Hara AK, Kofler JM, McCollough CH, Fidler JL, Guimaraes L, Huprich JE, Sandborn WJ, Loftus EV, Mandrekar J, Bruining DH. PMID: 20848546.
-
Why innovation in inflammatory bowel disease drug development will impact your practice. Clin Gastroenterol Hepatol. 2011 Mar; 9(3):211-3. Sandborn WJ. PMID: 21338946.
-
Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012 Jan; 18(1):43-8. Peyrin-Biroulet L, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 21351216; PMCID: PMC3352677.
-
Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis. 2012 Feb; 18(2):219-25. Bruining DH, Siddiki HA, Fletcher JG, Sandborn WJ, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Evans PE, Faubion WA, Hanson KA, Ingle SB, Pardi DS, Schroeder KW, Tremaine WJ, Loftus EV. PMID: 21337477.
-
Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011 May; 9(5):395-9. Bruining DH, Sandborn WJ. PMID: 21277392.
-
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar; 89(3):387-91. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium. PMID: 21270794; PMCID: PMC3098761.
-
Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch. Gastroenterology. 2011 Mar; 140(3):1107-8; author reply 1108-9. Levesque BG, Hanson KA, Sandborn WJ. PMID: 21272556.
-
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar; 33(5):541-50. Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. PMID: 21223344.
-
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. PMID: 21209123.
-
Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis. 2011 Jan; 17(1):105-11. Thia K, Faubion WA, Loftus EV, Persson T, Persson A, Sandborn WJ. PMID: 20629100.
-
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011 Jan; 17(1):141-51. Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P. PMID: 20848500.
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. PMID: 21157441.
-
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. PMID: 21104734.
-
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011 Jan; 33(2):194-202. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ. PMID: 21114791.
-
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011 Jun; 17(6):1415-22. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. PMID: 21560202; PMCID: PMC3116198.
-
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93. Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. PMID: 21083671.
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. PMID: 21045814.
-
The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis. Aliment Pharmacol Ther. 2010 Nov; 32(9):1207-9. Samuel S, Loftus EV, Sandborn WJ. PMID: 21039684.
-
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16(11):1912-21. Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 20848486.
-
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010 Nov; 59(11):1485-92. Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. PMID: 20947884.
-
Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2011 Jun; 17(6):1443-4. Levesque BG, Sandborn WJ. PMID: 21560204.
-
State-of-the-art: Immunosuppression and biologic therapy. Dig Dis. 2010; 28(3):536-42. Sandborn WJ. PMID: 20926883.
-
Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17(6):1257-64. Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. PMID: 20878712.
-
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg. 2010 Dec; 14(12):1859-65; discussion 1865-6. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW. PMID: 20872084.
-
Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan; 17(1):471-8. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 20725943.
-
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010 Oct; 139(4):1147-55. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. PMID: 20637205; PMCID: PMC2950117.
-
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010 Jun 16; (6):CD001176. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. PMID: 20556748.
-
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. PMID: 20491747.
-
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):688-695.e2. Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. PMID: 20451663.
-
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15; 362(15):1383-95. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, SONIC Study Group. PMID: 20393175.
-
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010 May; 105(5):1142-9. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. PMID: 20389296.
-
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR, PRECiSE 4 Study Investigators. PMID: 20363366.
-
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. PMID: 19714757.
-
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Jun; 31(12):1296-309. Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. PMID: 20298496.
-
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul; 105(7):1574-82. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ, PRECiSE 2 Study Investigators. PMID: 20234346.
-
How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis. 2009; 27 Suppl 1:80-4. Sandborn WJ. PMID: 20203501.
-
Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010 Jul; 105(7):1610-9. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. PMID: 20160714.
-
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. PMID: 20145610; PMCID: PMC6937708.
-
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators. PMID: 20117244.
-
Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010 Feb; 59(2):141-7. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 20176633.
-
Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010 Feb; 16(2):226-32. Guimarães LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H, Sandborn WJ, Loftus EV, Pardi DS, McCollough CH. PMID: 19637359.
-
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010 Apr; 8(4):357-63. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. PMID: 20096379.
-
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. PMID: 20064514.
-
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010 Jan; 16(1):15-22. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. PMID: 19610077.
-
Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg. 2010 Jan; 145(1):42-7. Malireddy K, Larson DW, Sandborn WJ, Loftus EV, Faubion WA, Pardi DS, Qin R, Gullerud RE, Cima RR, Wolff B, Dozois EJ. PMID: 20083753.
-
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb; 105(2):289-97. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 19861953.
-
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1599-604. D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn WJ, IOIBD Membership. PMID: 19653291.
-
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. PMID: 19766640.
-
Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1308-19. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. PMID: 19434735.
-
Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009 Sep; 15(9):1326-30. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV. PMID: 19235915.
-
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. PMID: 19408340.
-
Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther. 2009 Nov 01; 30(9):930-6. Manabe N, Cremonini F, Camilleri M, Sandborn WJ, Burton DD. PMID: 19678812; PMCID: PMC2862903.
-
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2768-73. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. PMID: 19672253.
-
Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol. 2009 Aug; 104(8):2097-9. Velayos FS, Sandborn WJ. PMID: 19661939.
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. PMID: 19596014.
-
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol. 2009 Jul; 193(1):113-21. Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV, Sandborn WJ, Pardi DS, Mandrekar JN. PMID: 19542402.
-
CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom Imaging. 2009 Jul; 34(4):467-75. Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA, Sandborn WJ, Loftus EV. PMID: 18551336.
-
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2009 Jul; 5(7):494-500. Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, Karlstadt RG, Diebold R, Joseph RE. PMID: 37967434; PMCID: PMC2886429.
-
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009 Oct; 104(10):2524-33. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. PMID: 19532125.
-
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W, Crohn's Disease Photopheresis Study Group. PMID: 19130617.
-
Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol. 2009 Oct; 7(10):1139. Peyrin-Biroulet L, Colombel JF, Sandborn WJ. PMID: 19465159.
-
Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis. 2009 May; 15(5):772-7. Hanson KA, Loftus EV, Harmsen WS, Diehl NN, Zinsmeister AR, Sandborn WJ. PMID: 19107782.
-
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009 Aug; 30(3):210-26. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. PMID: 19392858.
-
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. PMID: 19352339.
-
Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis. 2009 Apr; 15(4):566-75. Loftus EV, Friedman HS, Delgado DJ, Sandborn WJ. PMID: 19143006.
-
MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut. 2009 Sep; 58(9):1226-33. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. PMID: 19251712.
-
Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol. 2009 Apr; 104(4):868-76. Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. PMID: 19240707.
-
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul; 58(7):940-8. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. PMID: 19201775; PMCID: PMC2689393.
-
Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. PMID: 19174807.
-
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. PMID: 18671232.
-
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009 Jan; 15(1):17-24. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. PMID: 18668682.
-
The future of inflammatory bowel disease care. Rev Gastroenterol Disord. 2009; 9(3):E69-77. Sandborn WJ. PMID: 19898267.
-
Relationships between C-reactive protein concentration and genotype in healthy volunteers. Clin Chem Lab Med. 2009; 47(1):20-5. Jones J, Chen LS, Baudhuin L, Peterson S, Harmsen WS, Zinsmeister AR, McConnell J, Sandborn WJ. PMID: 19072030.
-
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. PMID: 18786111.
-
Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis. 2008 Dec; 14(12):1701-6. Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV. PMID: 18623171.
-
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008 Dec; 103(12):3167-82. Thia KT, Loftus EV, Sandborn WJ, Yang SK. PMID: 19086963.
-
AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States. Gastroenterology. 2008 Nov; 135(5):1764-89.e2. Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, McQuaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA, Sandborn WJ, Todisco A. PMID: 19009690.
-
Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008 Nov; 135(5):1442-7. Sandborn WJ. PMID: 18848556.
-
Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S232-3. Sandborn WJ. PMID: 18816658.
-
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008 Nov; 6(11):1218-24. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ. PMID: 18799360.
-
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Sep 15; 28(6):674-88. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. PMID: 18532990.
-
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. PMID: 18848553.
-
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008 Oct; 135(4):1130-41. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn's Disease Study Group. PMID: 18706417.
-
Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008 Jul 05; 372(9632):67-81. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. PMID: 18603161.
-
Certolizumab Pegol for Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2008 Jul; 4(7):467-8. Sandborn WJ. PMID: 21960919; PMCID: PMC3096126.
-
Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008 Jul; 103(7):1737-45. Loftus EV, Delgado DJ, Friedman HS, Sandborn WJ. PMID: 18564126.
-
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008 Aug; 103(8):2015-22. Peloquin JM, Pardi DS, Sandborn WJ, Fletcher JG, McCollough CH, Schueler BA, Kofler JA, Enders FT, Achenbach SJ, Loftus EV. PMID: 18564113; PMCID: PMC2831296.
-
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug; 68(2):255-66. Solem CA, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 18513722.
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun; 6(6):644-53. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. PMID: 18550004.
-
Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis. 2008 Jun; 14(6):850-7. Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH, Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. PMID: 18213696.
-
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group. PMID: 18602921.
-
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008 Apr 09; 299(14):1690-7. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P. PMID: 18398081.
-
Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008 Apr; 42(4):338-44. Sandborn WJ. PMID: 18277908.
-
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008 Jun 01; 27(11):1094-102. Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE. PMID: 18363894.
-
Initial combination therapy in early Crohn's disease. Lancet. 2008 Feb 23; 371(9613):635-636. Sandborn WJ. PMID: 18295013.
-
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008 Jul; 57(7):893-902. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. PMID: 18272546; PMCID: PMC2564831.
-
Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008 Feb; 103(2):407-15. Garrity-Park MM, Loftus EV, Bryant SC, Sandborn WJ, Smyrk TC. PMID: 18289203.
-
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr; 134(4):929-36. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. PMID: 18294633.
-
Mucosal healing in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(4):271-2. Sandborn WJ. PMID: 19107101.
-
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007 Dec; 102(12):2737-46. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. PMID: 18042106.
-
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. PMID: 18080055; PMCID: PMC2658575.
-
Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2007 Dec; 9(6):521-7. Velayos FS, Sandborn WJ. PMID: 18377806.
-
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ, Crohn's and Colitis Foundation of America Clinical Alliance. PMID: 17567869.
-
Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis. 2007 Oct; 13(10):1266-70. Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I, Sandborn WJ, Loftus EV, Pemberton JH. PMID: 17567877.
-
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007 Oct 01; 26(7):987-1003. Sandborn WJ, Feagan BG, Lichtenstein GR. PMID: 17877506.
-
Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol. 2007 Sep; 3(5):683-94. Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. PMID: 20477019.
-
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Sep; 13(9):1135-40. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. PMID: 17476675.
-
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. PMID: 17920064.
-
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. PMID: 17764676.
-
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):228-38. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators. PMID: 17634458.
-
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators. PMID: 17634459.
-
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007 Jul 15; 26(2):205-15. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. PMID: 17593066.
-
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. PMID: 17631151.
-
Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther. 2007 Jun 15; 25(12):1435-41. Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS, Sandborn WJ, Harmsen WS, Thapa P, Zinsmeister AR. PMID: 17539983.
-
A moveable feast. Clin Gastroenterol Hepatol. 2007 Jun; 5(6):646-7. Camilleri M, Sandborn WJ, Kolars JC, Murray JA, Poterucha JJ, Roberts L, Sinicrope FA, Wang KK. PMID: 17544990.
-
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12; 369(9573):1641-57. Baumgart DC, Sandborn WJ. PMID: 17499606.
-
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007 May; 204(5):956-62; discussion 962-3. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV, Sandborn WJ, Wolff BG, Pemberton JH. PMID: 17481518.
-
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. PMID: 17470824.
-
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007 May; 132(5):1672-83. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. PMID: 17484865.
-
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007 Mar; 13(3):254-61. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn WJ. PMID: 17206702.
-
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. PMID: 17324131.
-
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. PMID: 17299059; PMCID: PMC2701613.
-
European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3. Hanauer SB, Sandborn WJ. PMID: 17303600; PMCID: PMC1856750.
-
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):175-81. Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ, Sandborn WJ. PMID: 17206699.
-
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007 Apr; 102(4):829-36. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. PMID: 17222314.
-
Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007 Feb 01; 25(3):247-55. Desai D, Faubion WA, Sandborn WJ. PMID: 17217454.
-
Clinical perspectives in Crohn's disease: now and in the future. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S1-2. Sandborn WJ. PMID: 17392634.
-
A new treatment option for ulcerative colitis. Rev Gastroenterol Disord. 2007; 7(2):106-7. Sandborn WJ. PMID: 17597673.
-
Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S23-35. Sandborn WJ. PMID: 17392636.
-
Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. Hanauer SB, Sandborn WJ. PMID: 17392632.
-
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. PMID: 17234558.
-
Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):16-7. Sandborn WJ. PMID: 21960772; PMCID: PMC3096114.
-
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. PMID: 17258735.
-
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006 Dec; 12(12):1093-100. Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS, Sandborn WJ, Faubion WA. PMID: 17119382.
-
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007 Apr; 56(4):504-8. Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. PMID: 17135309; PMCID: PMC1856874.
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. PMID: 17241859.
-
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. PMID: 17241860.
-
Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006 Dec; 241(3):787-95. Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn WJ, Loftus EV, Harmsen WS. PMID: 17032911.
-
Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bowel Dis. 2006 Aug; 12(8):708-11. Laing AW, Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. PMID: 16917225.
-
Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. J Clin Gastroenterol. 2006 Aug; 40(7):587-91. Sands BE, Kilgore KM, Bloomfeld RS, Sandborn WJ. PMID: 16917398.
-
Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006 Aug; 12(8):669-76. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16917220.
-
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. PMID: 16825929.
-
Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):888-93. Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M, Onercept Study Group. PMID: 16797249.
-
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006 Jun; 130(7):1941-9. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. PMID: 16762617.
-
CLASSIC-I study the efficacy of adalimumab. Gastroenterology. 2006 May; 130(6):1929-30. Schreiber S, Sandborn WJ. PMID: 16697761.
-
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. PMID: 16678077.
-
What's new: innovative concepts in inflammatory bowel disease. Colorectal Dis. 2006 May; 8 Suppl 1:3-9. Sandborn WJ. PMID: 16594957.
-
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. PMID: 16606351.
-
Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006 Nov; 55(11):1561-7. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. PMID: 16648154; PMCID: PMC1860143.
-
Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006 Apr 15; 23(8):1087-96. Pardi DS, Sandborn WJ. PMID: 16611268.
-
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006 Nov; 55(11):1568-74. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. PMID: 16603634; PMCID: PMC1860086.
-
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006 Apr; 130(4):1039-46. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16618397.
-
CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006 Mar 01; 23(5):617-28. Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. PMID: 16480401.
-
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb; 4(2):203-11. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. PMID: 16469681.
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. PMID: 16472588.
-
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology. 2006 Feb; 238(2):505-16. Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV, Harmsen WS, Crownhart BS. PMID: 16436815.
-
Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006 Sep; 55(9):1248-54. Jess T, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16423890; PMCID: PMC1860022.
-
Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89. Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. PMID: 16957658.
-
Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006 Jan; 12(1):29-32. Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. PMID: 16374255.
-
Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord. 2006; 6(2):97-105. Sandborn WJ. PMID: 16699478.
-
Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S15-21. Sandborn WJ. PMID: 16378006.
-
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. PMID: 16339095.
-
Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2005 Dec; 7(6):485-91. Egan LJ, Sandborn WJ. PMID: 16313879.
-
Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005 Dec; 11(12):1080-4. Moolsintong P, Loftus EV, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. PMID: 16306770.
-
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. PMID: 16267322.
-
State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S3-12. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. PMID: 16254481.
-
Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8. Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. PMID: 16254479.
-
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. PMID: 16279903.
-
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct; 100(10):2239-47. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. PMID: 16181376.
-
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Aug; 11(8):707-12. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 16043984.
-
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. PMID: 16086715.
-
Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis. Surg Endosc. 2005 Sep; 19(9):1284-7. Larson DW, Dozois E, Sandborn WJ, Cima R. PMID: 16132322.
-
Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005 May; 11(5):428-34. Toruner M, Harewood GC, Loftus EV, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ. PMID: 15867581.
-
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. PMID: 15771759.
-
Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005 Mar; 54(3):321-2. Pardi DS, Sandborn WJ. PMID: 15710974; PMCID: PMC1774419.
-
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. PMID: 15709987.
-
Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71. Hanauer S, Sandborn WJ, Persson A, Persson T. PMID: 15709986.
-
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005 Jan; 54(1):91-6. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PMID: 15591511; PMCID: PMC1774346.
-
Inflammatory bowel disease: a new combination therapy for pouchitis. Rev Gastroenterol Disord. 2005; 5(2):110. Sandborn WJ. PMID: 15976743.
-
New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord. 2005; 5(1):10-8. Sandborn WJ. PMID: 15741928.
-
Clinical management of pouchitis. Gastroenterology. 2004 Dec; 127(6):1809-14. Sandborn WJ, Pardi DS. PMID: 15578518.
-
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004 Nov 11; 351(20):2069-79. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group. PMID: 15537905.
-
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004 Oct; 53(10):1485-93. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. PMID: 15361500; PMCID: PMC1774244.
-
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. PMID: 15447761.
-
Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005 Feb; 312(2):537-45. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. PMID: 15388785.
-
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology. 2004 Sep; 127(3):990-3. Sandborn WJ, Feagan BG. PMID: 15362055.
-
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):657-60. Velayos FS, Sandborn WJ. PMID: 15472531.
-
Biologics in inflammatory bowel disease: how much progress have we made? Gut. 2004 Sep; 53(9):1366-73. Sandborn WJ, Faubion WA. PMID: 15306602; PMCID: PMC1774209.
-
Medical therapy of Crohn disease. Curr Opin Gastroenterol. 2004 Jul; 20(4):351-9. Panaccione R, Sandborn WJ. PMID: 15703664.
-
Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):141-69, vii. Loftus CG, Egan LJ, Sandborn WJ. PMID: 15177532.
-
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004 Jun; 53(6):780-2. Sandborn WJ, Loftus EV. PMID: 15138201; PMCID: PMC1774089.
-
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98. Sandborn WJ, Hanauer SB, Buch A. PMID: 15142198.
-
Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004 May; 10(3):207-14. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 15290913.
-
Advances in the treatment of Crohn's disease. Gastroenterology. 2004 May; 126(6):1574-81. Egan LJ, Sandborn WJ. PMID: 15168368.
-
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004 May; 99(5):878-83. Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. PMID: 15128354.
-
Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum. 2004 May; 47(5):782-6. Matzke GM, Kang AS, Dozois EJ, Sandborn WJ. PMID: 15037928.
-
Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis. 2004 Feb; 10 Suppl 1:S35-7. Sandborn WJ. PMID: 15168829.
-
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Jan; 10(1):28-31. Thomas CW, Weinshenker BG, Sandborn WJ. PMID: 15058523.
-
Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004 Jan; 99(1):97-101. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 14687149.
-
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan; 126(1):19-31. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. PMID: 14699483.
-
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S25-33. Sandborn WJ. PMID: 15583528.
-
Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004; 4(4):167-74. Sandborn WJ. PMID: 15580151.
-
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):501-5. Sandborn WJ. PMID: 14602060.
-
Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S1-5. Sandborn WJ. PMID: 14697912.
-
AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee. PMID: 14598268.
-
Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003 Nov; 1(6):465-73. Loftus EV, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ. PMID: 15017646.
-
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003 Nov; 98(11):2372-82. Sandborn WJ, Yednock TA. PMID: 14638336.
-
Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003 Oct; 98(10):2239-44. Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. PMID: 14572574.
-
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology. 2003 Oct; 229(1):275-81. Wold PB, Fletcher JG, Johnson CD, Sandborn WJ. PMID: 12944602.
-
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. PMID: 12891539.
-
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003 Aug 01; 18(3):263-77. Sandborn WJ, Feagan BG. PMID: 12895211.
-
Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003 Jul; 9(4):237-45. Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. PMID: 12902847.
-
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. PMID: 12818275.
-
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. PMID: 12786629.
-
Diagnosis and management of pouchitis. Gastroenterology. 2003 May; 124(6):1636-50. Mahadevan U, Sandborn WJ. PMID: 12761722.
-
Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis. 2003 May; 9(3):137-53. Elson CO, Sartor RB, Targan SR, Sandborn WJ. PMID: 12792219.
-
Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 2003 Apr; 124(4):1140-5. Sandborn WJ. PMID: 12671907.
-
Cyclosporin for refractory ulcerative colitis. Gut. 2003 Feb; 52(2):172-3. Loftus CG, Loftus EV, Sandborn WJ. PMID: 12524395; PMCID: PMC1774959.
-
Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):105-17. Sandborn WJ. PMID: 12617886.
-
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42. Sandborn WJ, Hanauer SB. PMID: 12492730.
-
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72. Sandborn WJ, Hanauer SB. PMID: 12492177.
-
Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002 Dec; 97(12):2939-41. Sandborn WJ. PMID: 12492172.
-
Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol. 2002 Nov; 97(11):2829-33. Pardi DS, Ramnath VR, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 12425555.
-
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol. 2002 Sep; 97(9):2300-5. Solem CA, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Sandborn WJ. PMID: 12358248.
-
Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002 Sep; 8(5):311-6. Mahadevan U, Loftus EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. PMID: 12479645.
-
Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002 Aug; 123(2):468-75. Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ. PMID: 12145800.
-
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol. 2002 Jul; 97(7):1763-8. Ricart E, Taylor WR, Loftus EV, O'Kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 12135032.
-
Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002 May; 8(3):186-91. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV. PMID: 11979139.
-
Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002 May; 122(6):1592-608. Sandborn WJ, Targan SR. PMID: 12016425.
-
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr; 122(4):875-80. Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 11910338.
-
Microscopic colitis: a review. Am J Gastroenterol. 2002 Apr; 97(4):794-802. Pardi DS, Smyrk TC, Tremaine WJ, Sandborn WJ. PMID: 12003412.
-
The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002 Apr; 97(4):922-7. Ullman TA, Loftus EV, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. PMID: 12008669.
-
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr; 97(4):910-4. Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 12008668.
-
Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):1-20. Loftus EV, Sandborn WJ. PMID: 12122726.
-
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. PMID: 11832465.
-
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev Gastroenterol Disord. 2002; 2 Suppl 2:S9-15. Feagan BG, Sandborn WJ. PMID: 12478239.
-
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002 Jan; 16(1):51-60. Loftus EV, Schoenfeld P, Sandborn WJ. PMID: 11856078.
-
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002 Jan; 122(1):72-7. Dayharsh GA, Loftus EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. PMID: 11781282.
-
Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):471-6. Mahadevan U, Sandborn WJ. PMID: 11696284.
-
Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001 Nov 20; 135(10):906-18. Schwartz DA, Pemberton JH, Sandborn WJ. PMID: 11712881.
-
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001 Nov; 49(5):665-70. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. PMID: 11600469; PMCID: PMC1728511.
-
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001 Nov; 49(5):656-64. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn WJ. PMID: 11600468; PMCID: PMC1728490.
-
Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl. 2001 Jun 05; 757(1):1-9. Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW, Sandborn WJ. PMID: 11419732.
-
Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001 May; 48(5):591-2. Sandborn WJ. PMID: 11302950; PMCID: PMC1728293.
-
Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis. Am J Gastroenterol. 2001 May; 96(5):1522-8. Levy AM, Yamazaki K, Van Keulen VP, Burgart LJ, Sandborn WJ, Phillips SF, Kephart GM, Gleich GJ, Leiferman KM. PMID: 11374693.
-
Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology. 2001 May; 120(6):1483-4. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 11313319.
-
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn's Disease Study Group. PMID: 11313302.
-
Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001 May; 15(5):653-63. Coulie B, Camilleri M, Bharucha AE, Sandborn WJ, Burton D. PMID: 11328259.
-
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001 Mar; 96(3):722-9. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 11280541.
-
Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. PMID: 11280528.
-
Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis. 2001 Feb; 7(1):38-42. Mahadevan U, Sandborn WJ. PMID: 11233659.
-
Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep. 2000 Dec; 2(6):440-5. Sandborn WJ, Faubion WA. PMID: 11079044.
-
Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol. 2000 Dec; 95(12):3463-8. Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn WJ. PMID: 11151878.
-
Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis. 2000 Nov; 6(4):286-9. Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ, Sandborn WJ. PMID: 11149561.
-
Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct; 95(10):2831-7. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. PMID: 11051356.
-
Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000 Sep; 95(9):2308-12. Loftus EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 11007233.
-
Steroid-dependent Crohn's disease. Can J Gastroenterol. 2000 Sep; 14 Suppl C:17C-22C. Sandborn WJ. PMID: 11023556.
-
Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis. 2000 Aug; 6(3):157-64. Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, Leteurtre L, Cortot A, Sandborn WJ, Colombel JF, Desreumaux P. PMID: 10961587.
-
Therapy for Crohn disease. Curr Opin Gastroenterol. 2000 Jul; 16(4):318-23. Sandborn WJ. PMID: 17031095.
-
Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol. 2000 Jun; 95(6):1480-5. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, Harmsen WS, Zinsmeister AR, Melton LJ. PMID: 10894583.
-
Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology. 2000 Mar; 118(3):630-1. Faubion WA, Sandborn WJ. PMID: 10702217.
-
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000 Mar; 46(3):336-43. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. PMID: 10673294; PMCID: PMC1727835.
-
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. PMID: 10701144.
-
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2):CD000545. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. PMID: 10796557.
-
Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev. 2000; (2):CD001176. Sandborn W, McLeod R, Jewell D. PMID: 10796613.
-
A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999 Dec; 13(12):1597-604. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. PMID: 10594394.
-
Infliximab for the treatment of fistulas in patients with Crohn'S disease. Gastroenterology. 1999 Nov; 117(5):1247-8. Ricart E, Sandborn WJ. PMID: 10535892.
-
Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999 Nov; 5(4):239-45. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. PMID: 10579116.
-
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999 Sep 10; 274(37):26448-53. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ. PMID: 10473604.
-
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. PMID: 10464128.
-
Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999 Aug; 5(3):167-73. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. PMID: 10453372.
-
Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999 Aug; 117(2):429-32. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. PMID: 10419926.
-
Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis. 1999 Aug; 5(3):174-81. Louvet B, Buisine MP, Desreumaux P, Tremaine WJ, Aubert JP, Porchet N, Capron M, Cortot A, Colombel JF, Sandborn WJ. PMID: 10453373.
-
Mycophenolate mofetil for Crohn's disease? Lancet. 1999 Jul 03; 354(9172):3-4. Lowry PW, Sandborn WJ, Lipsky JJ. PMID: 10406354.
-
The appendix in ulcerative colitis: a not so innocent bystander. Gastroenterology. 1999 Jul; 117(1):272-3. Panaccione R, Sandborn WJ. PMID: 10381940.
-
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999 Jul; 117(1):49-57. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. PMID: 10381909.
-
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999 Jun; 116(6):1505-6. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. PMID: 10391741.
-
Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis. 1999 May; 5(2):104-6. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, Melton LJ. PMID: 10338379.
-
Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999 May; 5(2):98-103. Harewood GC, Loftus EV, Tefferi A, Tremaine WJ, Sandborn WJ. PMID: 10338378.
-
Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc. 1999 May; 74(5):495-501. Tremaine WJ, Sandborn WJ. PMID: 10319083.
-
A comparison of budesonide and mesalamine for active Crohn's disease. Gastroenterology. 1999 May; 116(5):1263. Lowry PW, Sandborn WJ. PMID: 10220523.
-
Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol. 1999 May; 94(5):1161-71. Sandborn WJ. PMID: 10235187.
-
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33. Sandborn WJ, Hanauer SB. PMID: 10338381.
-
Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology. 1999 Apr; 116(4):1001-2; discussion 1002-3. Panaccione R, Sandborn WJ. PMID: 10092326.
-
Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 1999 Mar; 44(3):602-7. Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn WJ, Larusso NF, Lindor KD. PMID: 10080157.
-
Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc. 1999 Feb; 49(2):153-7. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexander GL, Balm RK, Gostout CJ. PMID: 9925691.
-
Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis. 1999 Feb; 5(1):33-9. Sandborn WJ, McLeod R, Jewell DP. PMID: 10028447.
-
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999 Jan; 42(1):117-20. Muñoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. PMID: 10211531.
-
Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum. 1999 Jan; 42(1):186-7. Matteson EL, Orces CH, Duffy J, Lipsky JJ, Pike MG, Sandborn WJ. PMID: 9920030.
-
Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999 Jan; 65(1):29-39. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Fauq AH, Lipsky JJ. PMID: 9951428.
-
Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov; 115(5):1295-6. Egan LJ, Sandborn WJ. PMID: 9797390.
-
Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision. Aliment Pharmacol Ther. 1998 Jul; 12(7):679-84. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. PMID: 9701533.
-
Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: is it true and does it matter? Gastroenterology. 1998 Jul; 115(1):236-7. Sandborn WJ, Loftus EV, Ahlquist DA. PMID: 9649486.
-
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998 Jun; 114(6):1161-8. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. PMID: 9609752.
-
Nicotine carbomer enemas--pharmacokinetics of a revised formulation. Ital J Gastroenterol Hepatol. 1998 Jun; 30(3):260-5. Green JT, Rhodes J, Thomas GA, Evans BK, Feyerabend C, Russell MA, Sandborn WJ. PMID: 9759592.
-
Drug therapy of inflammatory bowel disease. Drugs Today (Barc). 1998 May; 34(5):431-46. Egan LJ, Sandborn WJ. PMID: 15010706.
-
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr; 26(4):386-92. Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. PMID: 9552133.
-
Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998 Apr; 93(4):504-14. Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. PMID: 9576439.
-
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998 Mar; 27(3):685-90. Loftus EV, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, Graziadei IW, Wiesner RH. PMID: 9500695.
-
Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer. 1998 Mar 01; 82(5):822-6. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. PMID: 9486569.
-
Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998 Mar; 93(3):442-8. Egan LJ, Sandborn WJ, Tremaine WJ. PMID: 9517654.
-
Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? Gastroenterology. 1998 Mar; 114(3):608-9. Sandborn WJ. PMID: 9496956.
-
Are short-chain fatty acid enemas effective for left-sided ulcerative colitis? Gastroenterology. 1998 Jan; 114(1):218-9. Sandborn WJ. PMID: 9428236.
-
Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998; 225:92-9. Sandborn WJ. PMID: 9515759.
-
Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 1997 Dec; 11(6):1041-6. Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. PMID: 9663827.
-
Nicotine enemas for active ulcerative colitis--a pilot study. Aliment Pharmacol Ther. 1997 Oct; 11(5):859-63. Green JT, Thomas GA, Rhodes J, Williams GT, Evans BK, Russell MA, Feyerabend C, Rhodes P, Sandborn WJ. PMID: 9354193.
-
A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Aliment Pharmacol Ther. 1997 Oct; 11(5):865-74. Compton RF, Sandborn WJ, Lawson GM, Sheets AJ, Mays DC, Zins BJ, Tremaine WJ, Lipsky JJ, Mahoney DW, Zinsmeister AR, Offord KP, Hurt RD, Evans BK, Green J. PMID: 9354194.
-
A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology. 1997 Sep; 113(3):1042-3. Sandborn WJ. PMID: 9288004.
-
6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology. 1997 Aug; 113(2):690-2. Sandborn WJ. PMID: 9247497.
-
Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther. 1997 Aug; 11(4):663-71. Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J. PMID: 9305473.
-
Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 1997 Aug; 40(8):971-2. Nyam DC, Pemberton JH, Sandborn WJ, Savcenko M. PMID: 9269816.
-
Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc. 1997 Jul; 72(7):616-20. Loftus EV, Tremaine WJ, Nelson RA, Shoemaker JD, Sandborn WJ, Phillips SF, Hasan Y. PMID: 9212762.
-
Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. J Clin Pharmacol. 1997 May; 37(5):426-36. Zins BJ, Sandborn WJ, Mays DC, Lawson GM, McKinney JA, Tremaine WJ, Mahoney DW, Zinsmeister AR, Hurt RD, Offord KP, Lipsky JJ. PMID: 9156375.
-
Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997 May; 92(5):876-9. Sandborn WJ. PMID: 9149205.
-
Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. Clin Pharmacol Ther. 1997 Mar; 61(3):340-8. Green JT, Thomas GA, Rhodes J, Evans BK, Russell MA, Feyerabend C, Fuller GS, Newcombe RG, Sandborn WJ. PMID: 9084459.
-
Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Mar 01; 126(5):364-71. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD. PMID: 9054280.
-
Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc. 1997 Feb; 72(2):117-23. Levy AM, Gleich GJ, Sandborn WJ, Tremaine WJ, Steiner BL, Phillips SF. PMID: 9033543.
-
Erythropoietin for inflammatory bowel disease anemia. Gastroenterology. 1997 Feb; 112(2):660-1. Sandborn W. PMID: 9024321.
-
A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology. 1997 Jan; 112(1):241-9. Compton RF, Sandborn WJ, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA, Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter AL, Plevy SE, Cominelli F, Targan SR, Rotter JI. PMID: 8978365.
-
A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol. 1997 Jan; 37(1):38-46. Zins BJ, Sandborn WJ, McKinney JA, Mays DC, van Os EC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. PMID: 9048271.
-
Does the surgical failure rate, increased incidence of pouchitis, and recent findings of dysplasia in pouches deter you from recommending an ileal pouch-anal anastomosis for ulcerative colitis? Inflamm Bowel Dis. 1997; 3(3):239-40. Sandborn WJ. PMID: 23282811.
-
Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis. 1997; 3(4):288-302. Loftus EV, Sandborn WJ, Lindor KD, Larusso NF. PMID: 23282876.
-
Long-term effects of antidepressants on balance, equilibrium, and postural reflexes. Psychiatry Res. 1996 Jul 31; 63(2-3):191-6. Li X, Hamdy R, Sandborn W, Chi D, Dyer A. PMID: 8878315.
-
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 1996 Jul; 39(1):63-8. Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. PMID: 8881811; PMCID: PMC1383233.
-
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996 May; 71(5):431-6. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. PMID: 8628021.
-
Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 1996 May; 110(5):1496-502. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. PMID: 8613055.
-
Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Apr 26; 679(1-2):147-54. Van Os EC, McKinney JA, Zins BJ, Mays DC, Schriver ZH, Sandborn WJ, Lipsky JJ. PMID: 8998554.
-
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996 Mar; 91(3):423-33. Sandborn WJ. PMID: 8633486.
-
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996 Feb; 110(2):432-40. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. PMID: 8566590.
-
Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996 Feb; 38(2):234-9. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. PMID: 8801203; PMCID: PMC1383029.
-
Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol. 1996 Jan; 91(1):37-43. Sandborn WJ, Tremaine WJ, Lawson GM. PMID: 8561141.
-
Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc. 1996 Jan; 71(1):69-80. Egan LJ, Sandborn WJ. PMID: 8538238.
-
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 Dec; 90(12):2177-81. Zins BJ, Sandborn WJ, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH, Dozois RR. PMID: 8540511.
-
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995 Dec; 109(6):1808-17. Sandborn WJ, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. PMID: 7498645.
-
Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology. 1995 Sep; 109(3):1001-3. Sandborn WJ. PMID: 7657085.
-
Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol. 1995 Sep; 90(9):1394-400. Zins BJ, Sandborn WJ, Tremaine WJ. PMID: 7661156.
-
Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci. 1995 Jul; 40(7):1474-83. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Rossi SS, Hofmann AF, Gores GJ, Phillips SF. PMID: 7628271.
-
Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 May; 90(5):740-7. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. PMID: 7733080.
-
Drug therapy for inflammatory bowel disease. Contemp Intern Med. 1995 Apr; 7(4):21-34. Loftus EV, Sandborn WJ. PMID: 10150344.
-
Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995 Jan; 21(1):70-6. Sandborn WJ, Lawson GM, Cody TJ, Porayko MK, Hay JE, Gores GJ, Steers JL, Krom RA, Wiesner RH. PMID: 7528712.
-
Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994 Dec; 107(6):1856-60. Sandborn WJ. PMID: 7958702.
-
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994 Jun; 106(6):1429-35. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. PMID: 8194687.
-
Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994 May; 69(5):409-15. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. PMID: 8170189.
-
Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr; 19(4):925-32. Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. PMID: 8138267.
-
High-volume postobstructive choleresis after transhepatic external biliary drainage resolves with conversion to internal drainage. J Clin Gastroenterol. 1993 Jul; 17(1):42-5. Sandborn WJ, Gross JB, Larson DE, Phillips JK, Lindor KD. PMID: 8409297.
-
Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993 May; 88(5):640-5. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. PMID: 8480724.
-
Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 1993 Feb; 34(2):242-6. Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. PMID: 8432481; PMCID: PMC1373978.
-
Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992 Oct; 67(10):981-90. Sandborn WJ, Tremaine WJ. PMID: 1434859.
-
Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1992 Aug; 15(2):125-9. Sandborn WJ, Goldman DH, Lawson GM, Perrault J. PMID: 1357126.
-
Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992 Jun; 15(6):1086-91. Sandborn WJ, Lawson GM, Krom RA, Wiesner RH. PMID: 1592348.
-
The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. J Clin Pharmacol. 1991 Jan; 31(1):76-80. Sandborn WJ, Strong RM, Forland SC, Chase RE, Cutler RE. PMID: 2045532.
-
Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. J Clin Pharmacol. 1990 Jun; 30(6):568-71. Sandborn WJ, Forland SC, Cutler RE, Strong RM. PMID: 2355107.
US